---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description. Covers Product description and Place of product in therapy. 284 evidence topics quoted from 115 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description

<a id="product-information-and-disease-description"></a>

## 2 Product Information and Disease Description

<a id="heading-2.1"></a>

### 2.1 Product Description

<a id="heading-2.1.1"></a>

#### 2.1.1 Phase of Product Development

<a id="topic-2.1.1-1"></a>

##### Regulatory status: Submission planned; BLA planned for mid-2027

> “to the FDA for ersodetug for one or both programs in mid-2027”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “We believe that we are well positioned to advance both congenital HI and tumor HI into the approval process next year and we look forward to discussions with FDA in the first quarter of 2027.”
> “the Company’s plans and expectations regarding a pre-BLA meeting and the potential submission of one or two Biologics License Applications (BLA) for ersodetug for both of tumor HI and congenital HI in 2027”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “Plan to submit a BLA for ersodetug for one or potentially both indications in 2027.”

Source: [Rezolute first quarter fiscal 2027 results release (2026)](https://ir.rezolutebio.com/news/detail/388/rezolute-reports-first-quarter-fiscal-2027-financial-results-and-provides-business-update)

<a id="topic-2.1.1-2"></a>

##### Launch

No evidence found.

<a id="topic-2.1.1-3"></a>

##### BLA submission strategy for tumor HI and congenital HI to be set after upLIFT results

> “In light of expected topline results this quarter from the Company’s upLIFT study in tumor HI and the potential for an additional pre-BLA meeting for that indication should the study results support a submission, the Company will evaluate its overall BLA submission strategy for potentially both programs following the announcement of upLIFT study results.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="topic-2.1.1-4"></a>

##### Phase 3 upLIFT study: preliminary primary endpoint result, November 2026

> “today announced positive results from the ongoing open-label Phase 3 upLIFT study of ersodetug in tumor HI, in which the primary efficacy endpoint has been achieved, based on preliminary results from a November 5th data evaluation.”
> “Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.1.1-5"></a>

##### Phase 3 upLIFT study: enrollment completed, October 2026

> “On October 14, 2026, we announced the completion of enrollment in upLIFT.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.1-6"></a>

##### FDA agreement to a single-arm, open-label upLIFT design, August 2025

> “At a meeting held with FDA on August 19, 2025, the agency agreed to modifications to the design of the study including removing the need to conduct a double-blind randomized placebo-controlled trial.”
> “The truncated study will include as few as 16 participants and will be limited to the single-arm open-label portion of the upLIFT study, which has been the focus of the Company’s patient recruitment efforts.”
> “FDA also confirmed that Rezolute’s pivotal sunRIZE trial in congenital HI, which is on track to report topline results in December 2025, would serve as confirmatory clinical evidence, and is demonstrative of FDA’s recognition of the broad applicability of ersodetug in multiple forms of HI.”

Source: [Rezolute upLIFT design alignment release (2025)](https://ir.rezolutebio.com/news/detail/361/rezolute-announces-alignment-with-fda-on-streamlined-design-for-ongoing-phase-3-trial-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-2.1.1-7"></a>

##### FDA breakthrough therapy designation for tumor HI, May 2025

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.”
> “BTD for ersodetug was granted based on clinical trial data across the overall program and a recognition of the mechanistic applicability to tumor HI, further validated by real-world experience in tumor HI patients who have been successfully treated with ersodetug throughout the U.S. in the Company's Expanded Access Program.”
> “In parallel and utilizing its BTD, the Company plans to engage further with FDA to discuss the registrational trial, including the necessary data package to support a BLA filing and potential approval for the tumor HI indication, as an expansion of the congenital HI indication.”

Source: [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.1-8"></a>

##### FDA orphan drug designation for tumor HI, November 2024

| Field | Quoted record |
| --- | --- |
| Generic name | “ersodetug” |
| Date designated | “11/20/2024” |
| Orphan designation | “treatment of hypoglycemia due to tumor-associated hyperinsulinism” |
| Orphan designation status | “Designated” |
| FDA orphan approval status | “Not FDA Approved for Orphan Indication” |
| Sponsor | “Rezolute Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)

> “today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI.”
> “Orphan Drug Designation offers benefits including seven years of market exclusivity protection and may shorten the clinical development path through potential qualification for expedited pathways to approval.”

Source: [Rezolute tumor HI orphan drug designation release (2024)](https://ir.rezolutebio.com/news/detail/343/fda-grants-orphan-drug-designation-to-rezolutes-ersodetug-rz358-for-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.1-9"></a>

##### FDA clearance of the IND for the tumor HI phase 3 study, August 2024

> “today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI).”
> “The Phase 3 registrational study is a double-blind, randomized, placebo-controlled trial of 24 participants who have inadequately controlled hypoglycemia because of tumor HI.”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.1-10"></a>

##### European Union orphan designation for insulinoma, January 2024

| Field | Quoted record |
| --- | --- |
| Active substance | “Ersodetug” |
| Intended use | “Treatment of insulinoma” |
| Orphan designation status | “Positive” |
| EU designation number | “EU/3/23/2879” |
| Date of designation | “12/01/2024” |
| Sponsor | “Rezolute (Bio) Ireland Limited” |

Source: [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879)

> “RZ358 also received Orphan Drug Designation status in the European Union for the treatment of Insulinoma, the primary cause of ICTH.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-2.1.1-11"></a>

##### Designations granted for congenital HI only

| Field | Quoted record |
| --- | --- |
| Generic name | “fully human IgG2 monoclonal antibody that binds insulin receptors” |
| Date designated | “06/09/2015” |
| Orphan designation | “Treatment of congenital hyperinsulinism” |
| Sponsor | “Rezolute, Inc.” |

Source: [FDA Orphan Drug Designations and Approvals (2015)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=430714)

> “Ersodetug has received Orphan Drug Designation in the U.S. and European Union for the treatment of congenital HI, as well as Rare Pediatric Disease Designation in the U.S., a prerequisite for a request for a Rare Pediatric Disease Priority Review Voucher upon BLA submission.”
> “ersodetug was subsequently granted a priority medicines (PRIME) designation by the European Medicines Agency (EMA), an Innovation Passport designation by the UK Innovative Licensing and Access Pathway (ILAP) Steering Group for the treatment of congenital HI, and Breakthrough Therapy Designation by the FDA in the U.S.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.1-12"></a>

##### Congenital HI program: FDA recommendation of a pre-BLA meeting, October 2026

> “The Agency has reviewed the data and, despite the trial’s failure to meet the prespecified primary and key secondary endpoints, as a next step, encouraged the Company to request a Type B pre-BLA meeting as a precursor to submitting a BLA for congenital HI.”
> “The Agency explicitly did not opine on the approvability of ersodetug for congenital HI and noted that any such determination would only be made as a part of an in-depth evaluation of the supporting data during a formal BLA review, as is customary during a BLA process.”

Source: [Rezolute pre-BLA recommendation release (2026)](https://ir.rezolutebio.com/news/detail/385/rezolute-announces-fda-recommendation-to-hold-a-pre-bla-meeting-as-a-precursor-to-submitting-a-biologics-license-application-bla-for-congenital-hyperinsulinism)

<a id="heading-2.1.2"></a>

#### 2.1.2 Product Information

<a id="heading-2.1.2.1"></a>

##### 2.1.2.1 Generic, Brand Name and Therapeutic Class of Product

<a id="topic-2.1.2.1-1"></a>

###### Manufacturer: Rezolute

> “Sponsor: Rezolute Inc.”

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)

> “Our lead clinical asset, ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “The Company’s antibody therapy, ersodetug, has been studied in clinical trials and used in real-world cases for the treatment of refractory hypoglycemia due to a variety of causes of HI.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.1-2"></a>

###### Commercial manufacturing by third parties

> “We also expect to rely upon third parties to produce materials required for the commercial production of our product candidates if we succeed in obtaining necessary regulatory approvals.”
> “We rely upon a small number of third-party suppliers for the manufacture of certain raw materials that are necessary to formulate our drug products for preclinical and clinical testing purposes.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.1-3"></a>

###### Licensor: XOMA, acquired by Ligand Pharmaceuticals in July 2026

> “pursuant to which XOMA granted an exclusive global license to the Company to develop and commercialize ersodetug for all indications.”
> “On July 14, 2026, XOMA was acquired by Ligand Pharmaceuticals Incorporated”
> “The next milestone payment of $25.0 million will be due upon regulatory approval for ersodetug by any regulatory authority.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.1-4"></a>

###### International nonproprietary name

> “ersodetug immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric”

Source: [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.1-5"></a>

###### Development codes and former names: XOMA 358 and RZ358

> “On 14 July 2016, orphan designation (EU/3/16/1702) was granted by the European Commission to XOMA UK Limited, United Kingdom, for the recombinant human monoclonal antibody to insulin receptor (also known as XOMA 358) for the treatment of congenital hyperinsulinism.”
> “The sponsorship was transferred to Rezolute (Bio) Ireland Limited, Ireland in June 2022”

Source: [EMA congenital hyperinsulinism orphan designation (2016)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-16-1702)

> “XOMA 358 (X358) is a fully human monoclonal antibody to the insulin receptor that acts as a negative allosteric modulator of insulin signaling.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

> “today announced that it received U.S. Food and Drug Administration (FDA) clearance for its Investigational New Drug (IND) application for RZ358 (ersodetug) to treat hypoglycemia in patients with tumor hyperinsulinism (HI).”

Source: [Rezolute tumor HI IND clearance release (2024)](https://ir.rezolutebio.com/news/detail/337/rezolute-announces-fda-clearance-of-ind-application-for-phase-3-registrational-study-of-rz358-for-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.2.1-6"></a>

###### Brand name

No evidence found.

<a id="topic-2.1.2.1-7"></a>

###### Therapeutic class: fully human monoclonal antibody, allosteric insulin receptor modulator

> “immunoglobulin G2-kappa, anti-[Homo sapiens INSR (insulin receptor)], Homo sapiens monoclonal antibody, allosteric”
> “produced in Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa”

Source: [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

> “Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia.”
> “Ersodetug for the treatment of HI is investigational.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="heading-2.1.2.2"></a>

##### 2.1.2.2 Dosage Forms and Strengths

<a id="topic-2.1.2.2-1"></a>

###### Vial concentration: 80 mg/mL

> “Each vial is 80 mg/mL”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

> “Each vial is 80 mg/mL”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="topic-2.1.2.2-2"></a>

###### Route of administration: intravenous infusion

> “Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “Administered by IV infusion”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.2-3"></a>

###### Vials per infusion at the tumor HI maintenance dose

> “Tumor HI maintenance dose: 9 mg/kg”
> “Adult patient average weight: ~80 kg”
> “Patients will use 9 vials per infusion on average”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.2-4"></a>

###### Formulation, fill volume, and storage

No evidence found.

<a id="heading-2.1.2.3"></a>

##### 2.1.2.3 Average Sales Price and Wholesale Acquisition Cost

Not applicable.

<a id="heading-2.1.2.4"></a>

##### 2.1.2.4 American Hospital Formulary Service (AHFS), or Other Drug Classification

<a id="topic-2.1.2.4-1"></a>

###### AHFS classification

No evidence found.

<a id="topic-2.1.2.4-2"></a>

###### WHO INN functional classification

> “insulin receptor allosteric inhibitor, antihypoglycaemic”

Source: [WHO INN Proposed List 128 (2022)](https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl128.pdf)

<a id="topic-2.1.2.4-3"></a>

###### Mechanistic class in company materials

> “Insulin receptor allosteric modulator”

Source: [Rezolute January corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926001556/tm262357d1_ex99-3.htm)

<a id="heading-2.1.2.5"></a>

##### 2.1.2.5 Indication

<a id="topic-2.1.2.5-1"></a>

###### Proposed indication: hypoglycemia due to tumor HI, as named in the FDA designations

> “Orphan Designation: treatment of hypoglycemia due to tumor-associated hyperinsulinism”

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723)

> “today announced the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ersodetug for the treatment of hypoglycemia due to tumor HI.”

Source: [Rezolute tumor HI orphan drug designation release (2024)](https://ir.rezolutebio.com/news/detail/343/fda-grants-orphan-drug-designation-to-rezolutes-ersodetug-rz358-for-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

> “today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia caused by tumor HI.”

Source: [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism)

<a id="topic-2.1.2.5-2"></a>

###### Population of the registrational study: insulinoma and non-islet cell tumors

> “The upLIFT Phase 3 registrational study is a single-arm, open-label, pivotal trial in approximately 16 participants with insulinoma or non-islet cell tumors who have uncontrolled hypoglycemia caused by tumor hyperinsulinism (HI).”
> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.5-3"></a>

###### European Union orphan designation: intended use in insulinoma

> “This medicine was designated as an orphan medicine for the treatment of insulinoma on 12 January 2024.”

Source: [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879)

<a id="topic-2.1.2.5-4"></a>

###### Approval status

> “Ersodetug for the treatment of HI is investigational. Statements about safety and efficacy have not been approved by any health authority.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="heading-2.1.2.6"></a>

##### 2.1.2.6 Pharmacology

<a id="heading-2.1.2.6.1"></a>

###### 2.1.2.6.1 Mechanism of Action

<a id="topic-2.1.2.6.1-1"></a>

###### Allosteric insulin receptor antibody acting in liver, fat, and muscle

> “Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle.”
> “The antibody down modulates insulin receptor activity, thereby helping to restore glucose to a more normalized range in conditions associated with elevated insulin or insulin-like substances (e.g. IGF-2 variants).”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.6.1-2"></a>

###### Selective and reversible reduction of insulin binding and signaling

> “The activity of insulin on target tissues is mediated by insulin receptor signaling, which causes increased glucose uptake into tissues, glycogen synthesis, suppression of gluconeogenesis, and suppression of free fatty acids and ketones ( 9 , 10 ).”
> “Ersodetug, a fully human insulin receptor–modulating antibody, engages an allosteric site on the insulin receptor to selectively and reversibly reduce insulin binding and signaling in a dose-dependent manner, leading to reduced insulin signaling ( 11 , 12 ).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.6.1-3"></a>

###### Modulation without blocking insulin binding

> “Insulin receptor modulating monoclonal antibody (IgG2)”
> “Allosterically binds to the insulin receptor in target tissue”
> “Does NOT block insulin binding”
> “Modulates insulin binding and signaling resulting in reduced glucose uptake from the bloodstream”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-2.1.2.6.1-4"></a>

###### Action on insulin and IGF-2 in both tumor types

> “Ersodetug is a fully human monoclonal antibody that binds allosterically to the insulin receptor to decrease receptor over-activation by insulin and related substances (such as IGF-2) in the setting of hyperinsulinism (HI), thereby improving hypoglycemia.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “The therapeutic potential of RZ358 in this setting was anticipated given that ICTH is mediated by insulin and that RZ358 is known to work at the insulin receptor to decrease excess insulin binding and activity.”
> “However, it was unknown if RZ358 would have utility in NICTH where hyperinsulinism is mediated by hormones such as insulin-like growth factor-2 (IGF-2) or its variants, which likewise cause hypoglycemia by binding to and activating the insulin receptor.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-2.1.2.6.1-5"></a>

###### Action downstream from the source of insulin

> “Because ersodetug acts downstream from the pancreas, it has the potential to be universally effective at treating hypoglycemia due to any congenital or acquired form of HI.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.6.1-6"></a>

###### Negative allosteric modulation: first-in-human publication

> “XOMA 358 (X358) is a fully human monoclonal antibody to the insulin receptor that acts as a negative allosteric modulator of insulin signaling.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.1-7"></a>

###### Identity of the discovery antibody XMetD with XOMA 358

> “For this purpose we employed XMetD [also known as XOMA358 (X358)], a human anti-INSR IgG2 monoclonal antibody, discovered by XOMA (US) LLC.”

Source: [Patel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150619/)

<a id="topic-2.1.2.6.1-8"></a>

###### Reduced insulin affinity and signaling efficacy: discovery studies of XMetD

> “Addition of insulin reduced the affinity of XMetD to the INSR by 3-fold, and XMetD reduced the affinity of the INSR for insulin 3-fold.”
> “In addition to inhibiting INSR binding, XMetD also inhibited insulin-induced INSR signaling by 20- to 100-fold.”
> “These data indicated that XMetD was an allosteric antagonist of the INSR because, in addition to inhibiting the INSR via modulation of binding affinity, it also inhibited the INSR via modulation of signaling efficacy.”

Source: [Corbin et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3929448/)

<a id="heading-2.1.2.6.2"></a>

###### 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

###### Circulating insulin as a biomarker of exposure: healthy volunteers

> “Dose-dependent elevations of circulating insulin levels, likely related to reduced insulin clearance via monoclonal antibody action at receptors, represented a sensitive biomarker of X358 exposure.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.2-2"></a>

###### Reduced insulin sensitivity after single infusions: healthy volunteers

> “X358-dependent increases in postprandial glucose levels and fasting homeostatic model assessment of insulin resistance values were observed and persisted for at least 1 week at the higher dose levels.”
> “In all the ITT cohorts, the slope for glucose lowering was substantially attenuated after X358 infusion of a similar magnitude, but with increasing duration with rising dose level.”
> “Single X358 infusions were well tolerated and resulted in a dose-dependent reduction in insulin sensitivity.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.2-3"></a>

###### Insulin biomarker response in congenital hyperinsulinism

> “there was evidence of pharmacologic activity as target therapeutic drug concentrations were achieved in both treatment groups (5 mg/kg and 10 mg/kg) with highly sensitive biomarker responses (increases in circulating insulin) in the active treatment groups that are indicative of reduced insulin activity at its receptor.”
> “Notably, these responses were consistent with those of the Company’s Phase 2 RIZE study (see Figure 1).”

Source: [Rezolute sunRIZE and EAP insights release (2026)](https://ir.rezolutebio.com/news/detail/369/rezolute-provides-insights-from-its-phase-3-sunrize-study-in-congenital-hyperinsulinism-and-shares-findings-from-its-expanded-access-program-in-tumor-hyperinsulinism)

<a id="topic-2.1.2.6.2-4"></a>

###### Inhibition of IGF-2 signaling at the insulin receptor: in vitro studies

> “To test this, the Company recently completed in vitro pharmacology studies to evaluate the impact of clinically relevant concentrations of RZ358 on insulin receptor activation by IGF-2, compared to insulin.”
> “These experiments successfully demonstrated the ability of RZ358 to similarly blunt both IGF-2 and insulin-mediated insulin-receptor signaling, at levels of these ligands that are disease-relevant in humans.”

Source: [Rezolute NICTH validation release (2024)](https://ir.rezolutebio.com/news/detail/327/rezolute-reports-validation-of-the-potential-use-of-rz358-for-treatment-of-non-islet-cell-tumor-hypoglycemia-nicth)

<a id="topic-2.1.2.6.2-5"></a>

###### Reversal of insulin-induced hypoglycemia in mice: XMetD

> “Intraperitoneal injection of XMetD at 10 mg/kg twice weekly into normal mice induced insulin resistance.”
> “When sustained-release insulin implants were placed into normal mice, they developed fasting hypoglycemia in the range of 50 mg/dl.”
> “This hypoglycemia was reversed by XMetD treatment.”

Source: [Corbin et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC3929448/)

<a id="topic-2.1.2.6.2-6"></a>

###### Prevention of fasting hypoglycemia in a mouse model of KATP hyperinsulinism

> “SUR-1−/− and wild-type mice received twice weekly intraperitoneal injections of either XMetD or control antibody for 8 wks.”
> “Treatment with XMetD significantly decreased insulin sensitivity, and increased hepatic glucose output and fasting plasma glucose.”

Source: [Patel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6150619/)

<a id="heading-2.1.2.6.3"></a>

###### 2.1.2.6.3 Pharmacokinetics

<a id="topic-2.1.2.6.3-1"></a>

###### Absorption, half-life, accumulation, and steady state: healthy volunteers and congenital hyperinsulinism

> “In healthy volunteers and individuals with congenital HI, ersodetug displays dose-proportional pharmacokinetics after intravenous administration, with peak serum concentrations observed within approximately 2 hours, an effective half-life of about 15 days (terminal elimination half-life 15-28 days), modest accumulation with repeat dosing, and concentrations that are predicted to approach or exceed 90% of steady-state within roughly 4-8 weeks depending on dosing frequency, with steady-state generally achieved by about 12 weeks.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.6.3-2"></a>

###### Single-dose half-life: healthy volunteers

> “X358 exhibited dose-proportional PK with a half-life of 21 days.”

Source: [Johnson et al. (2017)](https://pubmed.ncbi.nlm.nih.gov/28605468/)

<a id="topic-2.1.2.6.3-3"></a>

###### Half-life and potential for monthly dosing

> “Ersodetug shows dose dependent pharmacokinetics with a half-life greater than 2 weeks, which has the potential for monthly dosing.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.6.3-4"></a>

###### Repeat-dose pharmacokinetics: congenital hyperinsulinism

> “Ersodetug resulted in predictable, dose-proportional pharmacokinetics.”

Source: [Demirbilek et al. (2025)](https://www.cell.com/med/fulltext/S2666-6340(25)00038-8)

Additional sources: [ClinicalTrials.gov NCT04538989](https://clinicaltrials.gov/study/NCT04538989)

<a id="heading-2.1.2.7"></a>

##### 2.1.2.7 Contraindications/Warnings/Precautions/Adverse Effects

<a id="heading-2.1.2.7.1"></a>

###### 2.1.2.7.1 Warnings and Precautions

<a id="topic-2.1.2.7.1-1"></a>

###### FDA-approved prescribing information, contraindications, and boxed warnings

Not applicable.

<a id="topic-2.1.2.7.1-2"></a>

###### Serious hypersensitivity reactions: program-level incidence

> “Hypersensitivity reactions led to early discontinuation of study drug in 3 participants”
> “Two participants with serious allergic reactions (including anaphylaxis)”
> “Resolved quickly upon discontinuation of study drug”
> “Overall program incidence of ~2%”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

> “Two of the study participants experienced serious hypersensitivity reactions which led to early discontinuation of study drug.”
> “The incidence of serious allergic reactions across the program is relatively low compared to biologic or monoclonal antibody treatments.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.7.1-3"></a>

###### Known allergy to ersodetug: exclusion criterion in the tumor hyperinsulinism trial

> “Known allergy or sensitivity to ersodetug or any component of the drug.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.7.1-4"></a>

###### Hypertrichosis

> “Excess hair growth (hypertrichosis) was commonly reported in ersodetug treated patients (~35%)”
> “Mild and not dose-dependent”
> “Led to discontinuation of study drug in 1 participant”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

> “The most commonly reported study adverse event in ersodetug treated participants compared to placebo was hypertrichosis, which was generally mild and self-limiting.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.7.1-5"></a>

###### Hyperglycemia and hepatic safety monitoring: congenital hyperinsulinism program

> “No clinically-relevant hyperglycemia”
> “Low rates of transient mild to moderate hyperglycemia without associated sequalae”
> “No hyperglycemia AEs”
> “Hepatic safety: No signal by liver enzymes or ultrasound monitoring”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-2.1.2.7.1-6"></a>

###### Safety in tumor hyperinsulinism under expanded access

> “Ersodetug was generally safe and well tolerated among all individuals and across all dose levels and regimens.”
> “There were no drug-related deaths, adverse drug reactions, discontinuations due to adverse events, treatment-emergent clinically significant laboratory abnormalities indicative of organ toxicity, or other dose-limiting toxicities, as determined by treating physicians and reviewed by the sponsor's safety committee.”
> “No hyperglycemia-related adverse events or need for insulin were reported.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “No participants have discontinued the therapy due to lack of response or safety, and the duration of treatment has ranged from several months to more than 2 years in some instances, in this subset of tumor HI patients with significantly advanced and metastatic tumor burden.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.7.1-7"></a>

###### Nonclinical liver findings in Sprague Dawley rats

> “As part of the effort to resolve the partial clinical holds in the U.S., the Company conducted and recently completed an in-vivo toxicology study in brown Norway rats using Sprague Dawley (SD) rats as a positive control.”
> “Early results show that at the highest tested dose of 40 mg/kg, there were no observed liver abnormalities in the brown Norway rat, which is approximately four times higher than the dose that results in microvascular liver abnormalities in SD rats.”
> “Additionally, at the 40 mg/kg dose in this study, SD rats had liver abnormalities consistent with previous in-vivo studies.”
> “The Company believes that the Norway rat study adds to the body of evidence that the rat findings are specific to the SD rat and are not otherwise relevant, based on the absence of findings in other rat strains, other rodent species (CD-1 mice), primates, and humans in studies to date.”

Source: [Rezolute third quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/329/rezolute-reports-third-quarter-fiscal-2024-financial-results-and-provides-business-update)

<a id="topic-2.1.2.7.1-8"></a>

###### Partial clinical holds on congenital hyperinsulinism studies and their scope

> “In the January Meeting, FDA indicated that current dose caps on cHI studies would not be applicable to taHI studies.”
> “Therefore, considering the indication is primarily adult, current partial clinical holds pertaining to cHI studies would be largely irrelevant in taHI.”
> “The Company remains engaged with FDA in the attempt to resolve ongoing partial clinical holds on clinical studies in the cHI indication.”

Source: [Rezolute second quarter fiscal 2024 results release (2024)](https://ir.rezolutebio.com/news/detail/326/rezolute-reports-second-quarter-fiscal-2024-results-and-provides-business-update)

<a id="topic-2.1.2.7.1-9"></a>

###### Removal of the partial clinical holds in September 2024

> “today announced that the U.S. Food and Drug Administration (FDA) has removed the partial clinical holds on RZ358 (ersodetug), a potential treatment for hypoglycemia caused by congenital HI.”
> “are allowing us to proceed in the U.S. at all doses and in participants as young as three months of age as part of our ongoing global study”
> “FDA specifically concluded that the liver toxicity observed in Sprague Dawley rats is likely strain-specific and not otherwise relevant to humans”

Source: [Rezolute partial clinical hold release (2024)](https://ir.rezolutebio.com/news/detail/339/fda-lifts-partial-clinical-holds-on-rz358-for-the-treatment-of-congenital-hyperinsulinism-and-authorizes-u-s-inclusion-in-ongoing-phase-3-study)

<a id="heading-2.1.2.8"></a>

##### 2.1.2.8 Special Populations

<a id="topic-2.1.2.8-1"></a>

###### Pediatric and adult exposure: congenital hyperinsulinism

> “At the study dose regimens of 5 and 10 mg/kg administered every other week for 3 doses, followed by every 4 weeks over the remainder of the 24-week treatment duration, ersodetug target drug concentrations were achieved, across all age groups studied.”
> “Safety observations from the study were generally favorable and, in the opinion of the Company, support safe use of ersodetug in pediatric and adult patients.”

Source: [Rezolute sunRIZE topline release (2025)](https://ir.rezolutebio.com/news/detail/368/rezolute-announces-phase-3-sunrize-study-results-in-congenital-hyperinsulinism)

<a id="topic-2.1.2.8-2"></a>

###### Adults only in the tumor hyperinsulinism trial

> “Male or female participants of ≥18 years of age who provide written informed consent.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.8-3"></a>

###### Hepatic involvement and renal function: expanded access cohort

> “The cohort was characterized by predominantly metastatic disease with substantial hepatic involvement and variable but often abnormal liver biochemistry, along with renal function ranging from normal to mildly impaired at the time of ersodetug initiation.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.8-4"></a>

###### Cardiac, hepatic, or kidney disease: exclusion criterion in the tumor hyperinsulinism trial

> “Any organ condition, concomitant disease (e.g., psychiatric illness, severe alcoholism, or drug abuse, cardiac, hepatic, or kidney disease), or other abnormality that itself, or the treatment of which in the opinion of the investigator and/or Sponsor's Medical Monitor would pose an unacceptable risk to the participant in the study.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.8-5"></a>

###### Pregnancy and lactation

No evidence found.

<a id="heading-2.1.2.9"></a>

##### 2.1.2.9 Drug/Drug, Drug/disease Interactions

<a id="heading-2.1.2.9.1"></a>

###### 2.1.2.9.1 Effects of Other Drugs on Ersodetug

No evidence found.

<a id="heading-2.1.2.9.2"></a>

###### 2.1.2.9.2 Effects of Ersodetug on Other Drugs

No evidence found.

<a id="heading-2.1.2.10"></a>

##### 2.1.2.10 Dosing and Administration

<a id="heading-2.1.2.10.1"></a>

###### 2.1.2.10.1 Dosage

<a id="topic-2.1.2.10.1-1"></a>

###### Phase 3 regimen in tumor hyperinsulinism

> “Eligible participants requiring continuous parenteral dextrose will receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug in long-term extension, with the discretion to decrease the dosing frequency to every 2 to 4 weeks.”
> “Generally, dosing for tumor HI patients in the EAP has been either 6 mg/kg or 9 mg/kg every 1-4 weeks.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.10.1-2"></a>

###### Initiation, escalation, and de-escalation under expanded access

> “After exploratory dose-ranging in the first 2 participants, the initiation dose regimen was standardized in subsequent participants to 9 mg/kg weekly, followed by de-escalation as indicated.”
> “One participant required escalation from 9 to 12 mg/kg every other week.”
> “Glycemic stabilization was achieved across dosing regimens, with a more pronounced response observed in individuals initiated at 9 mg/kg weekly.”
> “More protracted responses to ersodetug and longer times to hospital discharge in initially treated individuals were associated with lower starting doses and less frequent administration of ersodetug (6 mg/kg and/or biweekly administration).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.10.1-3"></a>

###### Assumed maintenance dose and vial use for commercial planning

> “Tumor HI maintenance dose: 9 mg/kg”
> “117 vials per year per patient assuming infusion every four weeks”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-2.1.2.10.2"></a>

###### 2.1.2.10.2 Administration

<a id="topic-2.1.2.10.2-1"></a>

###### Intravenous infusion over 30 minutes

> “Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “30-min IV infusion given every 2-4 weeks”

Source: [ENDO Annual Meeting (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/ENDO_2026_ORF10_sunRIZE_Demirbilek_13June.pdf)

<a id="topic-2.1.2.10.2-2"></a>

###### Initiation in hospital and maintenance as an outpatient

> “After initiation of ersodetug, GIR was discontinued or substantially reduced, and hospitalized patients were able to be discharged and receive maintenance ersodetug doses on an outpatient basis, with durable benefit.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.10.2-3"></a>

###### Infusion setting for adolescents and adults

> “Patients aged 10 and older may benefit from flexible infusion options to minimize disruption to their daily routines”

Source: [Rezolute investor event presentation (2025)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925109559/tm2530840d1_ex99-1.htm)

<a id="heading-2.1.2.11"></a>

##### 2.1.2.11 Access and Distribution

<a id="topic-2.1.2.11-1"></a>

###### Expanded access: intermediate-size cohort program for tumor HI

> “This expanded access program is intended to provide ersodetug, an investigational drug, to eligible participants who suffer from inadequately controlled hypoglycemia due to tumor-associated hyperinsulinism and are unable to participate in ersodetug clinical trial.”
> “Participation is open to participants who meet the eligibility criteria and for whom access to the investigational drug is deemed appropriate by the treating physician.”

Source: [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970)

<a id="topic-2.1.2.11-2"></a>

###### Expanded access: company program and eligibility

> “Rezolute supports EAPs to help patients with serious conditions access investigational therapies like ersodetug.”
> “Our EAP is designed for patients who benefited from ersodetug during clinical trials and wish to continue treatment, or for those with severe, frequent low blood sugar due to high insulin levels who have no other options.”

Source: [Rezolute for patients page](https://rezolutebio.com/for-patients)

> “In the U.S., these requests have all been individually approved by the FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology - Division of Diabetes, Lipid Disorders, and Obesity.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.11-3"></a>

###### Expanded access: physician request and drug supplied at no cost

> “Enrollment was initiated by a treating physician through a named patient request (single-patient investigational new drug application) to the country health authority and was approved by local institutional review board, if required.”
> “Rezolute, Inc. (Redwood City, CA, USA) provided ersodetug at no cost to participating institutions for use under health authority–authorized compassionate use programs.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.11-4"></a>

###### Anticipated care setting at launch: National Cancer Institutes and academic medical centers

> “We believe 60% of these patients are managed at the National Cancer Institutes and academic medical centers, which will be our primary focus at launch.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “300 centers manage 60% of patients”
> “High penetration with a small number of treaters at National Cancer Institutes and Academic Medical Centers”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.11-5"></a>

###### Anticipated reimbursement: prior authorization and J-code buy and bill

> “Expect to manage ersodetug with a prior authorization aligned to the label and a step-through diazoxide for patients with insulinoma”
> “Reimbursement via J-code (buy and bill) simplifies the approval administration burden”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.1.2.11-6"></a>

###### Distribution rights in the Republic of Korea

> “whose CEO serves on the Company’s board of directors, entered into an exclusive license agreement”
> “The Handok License relates to pharmaceutical products in final dosage form containing the pharmaceutical compounds developed or to be developed by the Company, including those related to ersodetug and the PKI Portfolio.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.11-7"></a>

###### Specialty pharmacy or distribution network

No evidence found.

<a id="heading-2.1.2.12"></a>

##### 2.1.2.12 Co-prescribed/Concomitant Therapies

<a id="topic-2.1.2.12-1"></a>

###### Add-on to standard of care in the phase 3 trial

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”
> “Every study participant will receive ersodetug doses weekly for 8 weeks alongside their usual treatments for hypoglycemia at a dose of 9 mg/kg.”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.1.2.12-2"></a>

###### Background antihypoglycemic therapies weaned during expanded access

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/ kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “In several cases, other background medical therapies to prevent hypoglycemia were able to be weaned or stopped, and patients were able to resume tumor-directed therapies for treatment of their underlying cancer.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.1.2.12-3"></a>

###### Tumor-directed therapies given with ersodetug

> “Within 8 weeks of ersodetug initiation, nearly all individuals (n = 7) were able to proceed with tumor-directed therapies, including chemotherapy (n = 7), surgery (n = 4), and other medical procedures such as hepatic arterial embolization (n = 5).”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.1.2.12-4"></a>

###### Reduction of background therapy and monotherapy: congenital hyperinsulinism extension

> “These glycemic benefits have enabled a concurrent significant overall reduction in background SOC therapies (e.g., diazoxide, somatostatin analogs, and/or regular tube feeds), with a significant number of patients now receiving ersodetug as monotherapy, which we believe is a potential indicator of ersodetug’s underlying efficacy.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="heading-2.1.2.13"></a>

##### 2.1.2.13 Effect of Ersodetug on Quality Measures

<a id="topic-2.1.2.13-1"></a>

###### Hospital Harm, Severe Hypoglycemia electronic clinical quality measure (context; counts only events after a hypoglycemic medication)

| Field | CMS816v5 |
| --- | --- |
| Short name | “HH-Hypo” |
| Measure steward | “Centers for Medicare & Medicaid Services (CMS)” |
| Description | “The measure assesses the number of inpatient hospitalizations for patients age 18 and older who were administered at least one hypoglycemic medication during the encounter and who suffer the harm of a severe hypoglycemic event during the encounter” |
| Measure type | “Outcome” |
| Initial population | “Inpatient hospitalizations that end during the measurement period for patients age 18 and older and at least one hypoglycemic medication administration starts during the encounter” |
| Numerator | “Inpatient hospitalizations where a severe hypoglycemic event occurred during the encounter” |

Source: [eCQI Resource Center CMS816v5 (2026)](https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5)

<a id="topic-2.1.2.13-2"></a>

###### Hospital Harm, Severe Hypoglycemia electronic clinical quality measure: rationale

> “Inpatient hypoglycemia can be life-threatening, and is associated with longer hospital stays and increased medical costs.”
> “Severe hypoglycemia (<40 mg/dL) occurs in 2–5% of hospitalized patients with diabetes mellitus, and medication-related hypoglycemic events are common causes of adverse drug events occurring in inpatient settings.”
> “Rates of inpatient hypoglycemia events are considered an indicator of the quality of care provided by a hospital.”
> “Severe hypoglycemia events are largely avoidable by careful use of antihyperglycemic medication.”

Source: [eCQI Resource Center CMS816v5 (2026)](https://ecqi.healthit.gov/ecqm/hosp-inpt/2026/cms0816v5)

<a id="topic-2.1.2.13-3"></a>

###### Product-specific effect on quality measures

No evidence found.

<a id="heading-2.1.2.14"></a>

##### 2.1.2.14 Product comparison

<a id="topic-2.1.2.14-1"></a>

###### Diazoxide: the only FDA-approved drug labeled for hypoglycemia from inoperable islet cell tumors or extrapancreatic malignancy

> “PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions:”
> “Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.”
> “PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.”

Source: [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf)

<a id="topic-2.1.2.14-2"></a>

###### Ersodetug compared with current medical therapies: manufacturer statements on site of action and limitations of comparators

> “Because ersodetug acts downstream from pancreatic insulin or paraneoplastic IGF-2 secretion, and from entero-incretin pathways, it has the potential to be universally effective at treating refractory hypoglycemia due to any form of HI, including congenital HI, tumor HI (insulinoma, non-islet cell tumors) or bariatric/non-bariatric gastrointestinal surgery hypoglycemia.”
> “Ersodetug for the treatment of HI is investigational.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “Diazoxide (DZ) is the only approved treatment but has suboptimal response rates and serious side effects”
> “Somatostatin analogs (SSAs) are used off-label with limited success, and may cause paradoxical worsening of hypoglycemia”
> “mTOR-inhibitors are used off-label and have potentially serious side effects”
> “DZ and SSAs do not work in NICTs because HI is not mediated by insulin”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Currently available medical therapies are directed at reducing or eliminating insulin production and/or secretion from tumors, which may be challenging when the tumor is differentiated or dysregulated, and therefore not responding to usual control mechanisms for suppressing insulin production.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.1.2.14-3"></a>

###### Everolimus: labeled indication in pancreatic neuroendocrine tumors and hyperglycemia incidence

> “AFINITOR is indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.”
> “Hyperglycemia, hypercholesterolemia, and hypertriglyceridemia have been reported in patients taking AFINITOR/AFINITOR DISPERZ at an incidence up to 75%, 86%, and 73%, respectively.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.1.2.14-4"></a>

###### Tumor-directed agents with neuroendocrine tumor indications: lutetium Lu 177 dotatate and cabozantinib

> “LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”

Source: [Lutathera prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf)

> “CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).”

Source: [Cabometyx prescribing information (2025)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s019lbl.pdf)

<a id="topic-2.1.2.14-5"></a>

###### Hypoglycemia control across systemic therapies in malignant insulinoma: Mayo Clinic cohort

> “This study retrospectively analyzed 57 patients treated for malignant insulinoma at Mayo Clinic sites between 1992 and 2024, focusing on the efficacy of systemic therapies in improving hypoglycemic control and survival outcomes.”
> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.1.2.14-6"></a>

###### Alpelisib: off-label use in insulin- or proinsulin-producing tumors

> “We present a case series describing the effectiveness and tolerability of the phosphatidylinositol 3-kinase inhibitor alpelisib in 2 women with metastatic insulin-producing or proinsulin-producing tumors.”
> “For the first patient, the proportion of glucose readings <54 mg/dL fell from 2.3% (95% CI, 2.1-2.4) to 0.2% (95% CI, 0.2%-0.3%), and the rate ratio was 0.087 (95% CI, 0.086-0.089).”
> “Due to high cost and off-label use, the process of obtaining alpelisib was complex and took several months for the first patient and 2 years for the second patient.”

Source: [Ryan et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12268652/)

<a id="topic-2.1.2.14-7"></a>

###### Direct comparisons of ersodetug with other therapies

No evidence found.

Additional sources: [Cahn et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/37195951/)

<a id="heading-2.2"></a>

### 2.2 Place of Product in Therapy

<a id="heading-2.2.1"></a>

#### 2.2.1 Disease Description

<a id="heading-2.2.1.1"></a>

##### 2.2.1.1 Definition and Etiology

<a id="topic-2.2.1.1-1"></a>

###### Tumor hyperinsulinism as defined by the manufacturer: islet cell and non-islet cell tumors

> “Tumor hyperinsulinism (HI) is a rare disease that may be caused by two distinct types of tumors: islet cell tumors (ICTs) and non-islet cell tumors (NICTs), both of which lead to hypoglycemia because of over-activation of the insulin receptor.”
> “Insulinomas are the most common type of ICT and cause hypoglycemia via the overproduction of insulin.”
> “A variety of different NICTs, including hepatocellular carcinoma and soft tissue malignancies (e.g. sarcomas), can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances, such as variants of IGF-2, that bind to and activate the insulin receptor.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.1.1-2"></a>

###### Tumor types named by the manufacturer: insulinoma and non-islet cell tumors

> “Insulinomas are the most common type of functional ICT and mediate hypoglycemia through excessive insulin production.”
> “NICTs are generally associated with relatively large, solid tumors such as hepatocellular carcinoma, fibrosarcoma and mesothelioma, and can cause hypoglycemia by producing and secreting insulin-like paraneoplastic substances such as IGF-2 or related variants that bind to and activate the insulin receptor.”
> “This form of hypoglycemia can occur in more than 15 different types of tumors.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

> “Ultra-rare disease caused by tumors that produce insulin or insulin-like substances such as IGF-2”
> “Malignant insulinomas are the most common ICTs that cause hypoglycemia”
> “Hepatocellular carcinomas (HCC) are the most common NICTs that cause hypoglycemia in addition to several other tumor types including fibrosarcomas and mesotheliomas”
> “Over 16 different tumors have been linked to IGF-2, including liver, stomach, lung, breast, ovary, sarcomas, colorectal, esophageal, and others”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.1-3"></a>

###### Tumor hyperinsulinism as defined in the first expanded access report

> “Tumor hyperinsulinism (tumorHI) occurs when insulin or related paraneoplastic substances produced in excess by tumors stimulate the insulin receptor, leading to excessive signaling and hypoglycemia.”
> “TumorHI arises from two types of neoplasms: pancreatic neuroendocrine tumors (pNETs), i.e. insulinomas, and a variety of other tumors, which can oversecrete forms of IGF-2.”

Source: [Strosberg et al. (2024)](https://rezolutebio.com/wp-content/uploads/2025/10/NANETS-2024-Poster_Final.pdf)

<a id="topic-2.2.1.1-4"></a>

###### Insulinoma: definition and tumor location

> “Insulinomas are hormone-producing pancreatic neuroendocrine neoplasms with an estimated incidence of 1 to 4 cases per million per year. Extrapancreatic insulinomas are extremely rare.”
> “More than 99% of insulinomas are located in the pancreas, where its tumor locations are evenly distributed”
> “Approximately 10% of insulinomas present as multiple lesions”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.1-5"></a>

###### Insulinoma: aggressive (malignant) and indolent (benign) forms

> “Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent”
> “Secondary, or metachronous insulin secretion by panNEN that previously were nonsecreting, or secreting other peptide hormones, can also occasionally develop and is generally associated with a poor survival as compared with their non-insulin-secreting counterparts”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Malignancy was defined by distant metastases, positive lymph node(s), T stage of 4, direct invasion into surrounding peripancreatic tissue, or presence of lymphovascular invasion.”
> “A total of 311 patients were identified: 51 malignant and 260 benign.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.1-6"></a>

###### Insulinoma: hereditary etiology in multiple endocrine neoplasia type 1

> “A total of 5% to 10% of insulinomas are associated with the multiple endocrine neoplasia type 1 (MEN1) syndrome.”
> “The MEN1-related insulinomas may develop as multiple synchronous or metachronous lesions and are generally diagnosed at an earlier age than their sporadic counterparts because of application of the MEN1 screening recommendations”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.1-7"></a>

###### Non-islet cell tumor hypoglycemia: definition

> “Paraneoplastic hypoglycemia, also known as non-islet cell tumor hypoglycemia (NICTH), refers to hypoglycemia caused by or associated with tumors other than insulinoma. A wide range of epithelial, vascular or mesenchymal-origin neoplasms have been linked with NICTH”
> “Most cases of paraneoplastic hypoglycemia are attributed to the tumor's ability to produce insulin-like growth factor 2 (IGF-2) and its precursors, which activate insulin receptors, thereby enhancing glucose utilization”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “In closing, we replace non-islet-cell tumor hypoglycemia, an outdated and misleading label, with IGF-2-oma, self-explanatory and consistent with names of other hormone-secreting tumors.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.1-8"></a>

###### Non-islet cell tumor hypoglycemia: associated tumor types

> “The most common tumours associated with IGF‐2‐mediated hypoglycaemia were fibrous tumours (N = 124, 53.2%), followed by non‐fibrous tumours originating from the liver (N = 21, 9%), hemangiopericytoma (N = 20, 8.5%) and mesothelium (N = 11, 4.7%).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “we analyzed the medical records of 78 patients with NICTH (M/F 44/34, age 62+/-1.8, range; 9-86 years.) whose serum contained a large amount of big IGF-II. Hepatocellular carcinoma and gastric carcinoma were the most common causes of NICTH.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Among epithelial cancers, hepatocellular carcinomas are the most common, followed by adrenocortical tumors. Vascular tumors like hemangiopericytomas may also be linked to NICTH. In mesenchymal neoplasms, mesotheliomas and fibrosarcomas are the most frequently associated with paraneoplastic hypoglycemia.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

<a id="heading-2.2.1.2"></a>

##### 2.2.1.2 Epidemiology

<a id="heading-2.2.1.2.1"></a>

###### 2.2.1.2.1 Incidence of Tumor hyperinsulinism

<a id="topic-2.2.1.2.1-1"></a>

###### Insulinoma, Finland, 1980 to 2010: nationwide incidence in adults

> “Retrospective analysis on all adult patients diagnosed with insulinoma in Finland during 1980–2010.”
> “Seventy-nine patients were diagnosed with insulinoma over the research period.”
> “The incidence of insulinoma over the whole research period was 0.6 per million adults per year and increased remarkably during the study period (0.5, 0.4, and 0.9/million/year in the 1980s, 1990s, and 2000s, respectively).”
> “In Poisson regression analysis, the yearly incidence rate ratio was 1.043, and the increase in incidence was statistically significant (p = 0.002).”
> “In the patient record and pathology registry data, the insulinomas were classified as benign in 58 (73%), malignant in 11 (14%), and undetermined in 6 (8%) patients, using the contemporary classifications of PNENs. Distant metastases were documented in 9 (11%) patients.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

<a id="topic-2.2.1.2.1-2"></a>

###### Insulinoma, Western Sweden, 2002 to 2019: regional incidence

> “Medical records were reviewed for all patients in the VGR who had received an ICD-10 diagnosis code of a benign (D13.7) and/or a malignant (C25.4) tumor in the endocrine part of the pancreas, of hypoglycemia (E.161), and/or a code of a fasting test (AB011), from 2002-2019.”
> “Forty-two patients with insulinoma were identified, 37 of whom (20 men) were residents in the VGR at the time of diagnosis, giving a mean annual incidence of 1.3 cases per million/year.”
> “Six of the 37 (16%) patients had metastatic insulinoma and 2 patients (5%) had a confirmed multiple endocrine neoplasia type 1 syndrome.”
> “Our results do not support an increasing incidence of insulinoma.”

Source: [Svensson et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9210785/)

<a id="topic-2.2.1.2.1-3"></a>

###### Insulinoma, Olmsted County, Minnesota, 1927 to 1986: population-based incidence

> “With use of the complete medical record system at Mayo and the comprehensive epidemiologic data base of residents of Olmsted County, Minnesota, we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.”
> “During the study period, eight cases of insulinoma occurred among residents of Olmsted County; their age and gender distributions were similar to those of the total cohort.”
> “The incidence of insulinoma among residents of Olmsted County increased during the study period to a stable level during the last 2 decades of 4 cases per 1 million person-years.”
> “For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.2.1-4"></a>

###### Benign and malignant insulinoma, Japan, 2012: incidence from a national inpatient database

> “Using the Japanese Diagnosis Procedure Combination database, we retrospectively identified patients with insulinoma admitted between 2010 and 2018.”
> “We also estimated the incidence of insulinoma using the number of patients with newly diagnosed insulinoma in 2012.”
> “We identified 844 patients with benign insulinoma and 102 patients with malignant insulinoma.”
> “The incidence of insulinoma was estimated to be 3.27 (95% CI, 2.93-3.61) individuals per million Japanese adult population per year.”

Source: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

<a id="topic-2.2.1.2.1-5"></a>

###### Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey onset incidence

> “The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.”
> “Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).”

Source: [Ito et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24499825/)

<a id="topic-2.2.1.2.1-6"></a>

###### Malignant insulinoma, United States, 1973 to 2015: SEER registry incidence

> “We identified all patients with malignant insulinoma in the SEER registries from 1973 to 2015.”
> “A total of 121 patients were identified. The crude annual overall incidence was low (range 0.0–0.27 cases per million person years).”
> “The crude annual overall incidence was extremely low, but increased over the study period, from 0.0 to 0.17 cases per million person years. The annual overall incidence reached its peak in 2011 and 2012, at 0.27 cases per million person years. Most recently, the incidence was reported to be 0.17 cases per million person years in 2015.”
> “The largest proportion had localized disease (40%), while 16% had regional disease, 39% distant metastatic disease, and stage was unreported in 5%.”
> “We were unable to compare our observations to benign insulinoma as those cases are not captured by SEER.”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.1.2.1-7"></a>

###### Insulinoma: range of reported incidence across studies (review)

> “Insulinomas are the most common, yet still rare, hormone-producing pancreatic neuroendocrine neoplasms (panNEN) with a reported incidence of 0.7 to 4 cases per million per year”
> “There is an age-specific incidence peak in the fifth decade of life in men and the sixth decade of life in women and the incidence is slightly higher in women than in men”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.2.1-8"></a>

###### Non-islet cell tumor hypoglycemia: review estimate of incidence

> “In clinical practice, non‐islet cell tumour hypoglycaemia (NICTH) is considered a rare condition, with an incidence rate of one per million person‐years.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.2.1-9"></a>

###### Tumor hyperinsulinism, United States: company estimate of about 3,000 patients per year (September 2026)

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 3,000 patients in the U.S. alone per year.”

Source: [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm)

<a id="topic-2.2.1.2.1-10"></a>

###### Tumor hyperinsulinism, United States: company estimate of about 4,000 patients per year (November 2026)

> “While we believe the total addressable market may be larger, the immediately addressable incidence market for the combined indications causing tumor HI is estimated to be approximately 4,000 patients in the U.S. alone per year.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-2.2.1.2.2"></a>

###### 2.2.1.2.2 Prevalence of Tumor hyperinsulinism

<a id="topic-2.2.1.2.2-1"></a>

###### Benign and malignant insulinoma, Japan, 2017 to 2018: nationwide survey prevalence

> “A nationwide, questionnaire‐based survey was carried out to determine the number of patients with EHH who were treated for hypoglycemia or hypoglycemia‐related complications in 2017−2018.”
> “205 with insulinoma (118 benign, 18 malignant and 69 unknown subtype)”
> “The estimated prevalence was 0.16 per 100,000 population.”
> “insulinoma was more prevalent among female patients than among male patients (140/65), although the sex difference was smaller in those with malignant cases (10/8).”
> “compared with the pediatric clinics, the response rate from the adult clinics was lower (68.1% vs 38.2%), which might have affected the estimated prevalence of each EHH disorder.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.2.2-2"></a>

###### Pancreatic neuroendocrine tumors including insulinoma, Japan, 2010: nationwide survey of treated patients

> “Here, we conducted the second nationwide survey on patients with GEP-NETs who received treatment in 2010.”
> “A total of 3,379 patients received treatment for PNETs in 2010, representing a 1.2-fold increase in the number of patients from 2005 to 2010. The prevalence was estimated to be 2.69/100,000, with an annual onset incidence of 1.27/100,000 in 2010.”
> “Non-functioning tumor (NF)-PNETs comprised 65.5% of cases followed by insulinoma (20.9%) and gastrinoma (8.2%).”

Source: [Ito et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/24499825/)

<a id="topic-2.2.1.2.2-3"></a>

###### Non-islet cell tumor hypoglycemia: review estimate of prevalence relative to insulinoma

> “The true prevalence and clinical impact of hypoglycaemia induced by NICTH remains uncertain in the current medical literature. However, it is estimated to be four times less prevalent than insulinoma.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.2.2-4"></a>

###### Gastrointestinal stromal tumor, Japan, 2011 to 2023: hypoglycemia from any cause and NICTH at one institution

> “Eight patients out of 195 patients met this criteria (4.1%). The causes of hypoglycemia were diverse, including tumor growth, adverse drug effects, post-operation, liver failure, and unknown”
> “Hypoglycemia was observed in 4.1% of patients with GISTs (all stages) and 14.2% of patients with unresectable/metastatic GISTs.”
> “The present study identified 1 case with recurrent hypoglycemia due to NICTH.”

Source: [Chida et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11465228/)

<a id="topic-2.2.1.2.2-5"></a>

###### Malignant insulinoma, United States, October 2026: company point-in-time estimate from claims data

> “~2,500 Addressable Malignant Insulinoma Patients in the U.S.”
> “Malignant insulinoma patients (includes C25.4, hypoglycemia, CGM, supporting symptoms”
> “The ICD-10 code C25.4 is for malignant neoplasm of the endocrine pancreas, or cancer of the endocrine pancreas”
> “Point-in-time prevalence as of Oct 2026. Source: Veeva Compass database; covers more than 70% of US patients, 4M+ providers, 120B+ records, and 8+ years of patient history.”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.2.2-6"></a>

###### Non-islet cell tumor hypoglycemia, United States, October 2026: company point-in-time estimate from claims data

> “~1,500 Addressable NICTH Patients in the U.S.”
> “Dextrose, oral glucocorticoids, and glucagon (diazoxide and somatostatin analogs are not effective treatments for hypo from IGF-2 tumors)”
> “Point-in-time prevalence as of Oct 2026.”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.2.2-7"></a>

###### Tumor hyperinsulinism, United States: company total of about 4,000 patients

> “Tumor HI: ~4,000 patients; $4-5B TAM”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-2.2.1.3"></a>

##### 2.2.1.3 Natural History, Survival, and Mortality

<a id="topic-2.2.1.3-1"></a>

###### Insulinoma: survival by indolent or aggressive behavior across published series

> “Approximately 10% to 15% of insulinomas belong to the aggressive category and 85% to 90% can be considered as indolent”
> “Patients with an aggressive insulinoma have lower survival compared with patients with an indolent insulinoma.”
> “The 5-year survival of patients with an indolent insulinoma has been reported to be 94% to 100% and for patients with an aggressive insulinoma this amounts to 24% to 67%”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.3-2"></a>

###### Insulinoma: survival of non-metastatic and metastatic disease in a nationwide Finnish cohort

> “Overall survival was analysed with Kaplan–Meier and Cox regression analyses.”
> “During the follow-up, 25 (32%) patients and 63 (20%) controls deceased.”
> “In a Cox regression analysis, the median overall survival of 27.5 (95% CI: 24.1–30.8) years in the patients with a non-metastatic insulinoma did not significantly differ from the 33.2 (29.8–36.7) years in their controls (HR: 1.5 (0.9–2.6), P = 0.128).”
> “In the patients with a metastatic insulinoma, the survival was significantly impaired, with a median of 3.4 (2.9–4.0) years vs not reached in the controls (HR: 5.1 (1.9–13.3), P = 0.001).”
> “Three of the patients with metastatic insulinoma (33%), however, showed a remarkably long survival time of 6–30 years.”
> “In the multivariate analyses, older age and distant metastases were associated with decreased survival”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.3-3"></a>

###### Insulinoma: causes of death and perioperative mortality in a nationwide Finnish cohort

> “Nine of the 25 insulinoma patients who deceased during the study period (36%) died due to an insulinoma-related cause: 6 patients died of metastatic insulinoma, 2 patients died of surgical complications, and 1 patient died due to complications of invasive diagnostics, as previously described”
> “With the two deaths due to surgical complications, the perioperative mortality, defined as any death occurring within 30 days after surgery, was 2.7%.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.3-4"></a>

###### Insulinoma: recurrence after curative-intent surgery

> “the 5-, 10-, and 15-years disease-free survival rates were 94, 93, and 90%, respectively.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

> “The risk of recurrence was greater among patients with MEN I (21% at 10 and 20 years) than in those without MEN I (5% at 10 years and 7% at 20 years).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.3-5"></a>

###### Insulinoma: long-term survival of a 60-year Mayo Clinic cohort

> “we found 224 patients in whom an initial pancreatic exploration at Mayo had confirmed the presence of insulinoma.”
> “For the total cohort, 7.6% had multiple endocrine neoplasia type I (MEN I), and 5.8% had malignant insulinoma.”
> “Although survival of the total cohort was not significantly impaired, it was significantly worse than expected for patients with malignant insulinoma (29% versus 88% expected at 10 years postoperatively).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.1.3-6"></a>

###### Insulinoma: survival of benign versus malignant disease at a single institution

> “A total of 311 patients were identified: 51 malignant and 260 benign.”
> “Overall survival at 5 years was 66.8% vs 95.4% for malignant and benign insulinoma respectively, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.3-7"></a>

###### Malignant insulinoma: population-based survival in the SEER registries

> “A total of 121 cases of malignant insulinoma were identified between 1973 and 2015.”
> “The median overall survival (OS) was 143 months, with 5-and 10-year OS observed in 58% and 55%, respectively”
> “5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.”
> “On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.1.3-8"></a>

###### Malignant insulinoma: survival and prognostic factors in an Italian multicenter series

> “Multicenter retrospective study on 31 patients (male: 61.3%) diagnosed between 1988 and 2017.”
> “The 5-year survival rate was 62%.”
> “Overall survival was significantly higher in patients with Ki-67 ≤10% (P = 0.03), insulin level <60 µU/mL (P = 0.015) and in patients who underwent surgery (P = 0.006).”

Source: [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/)

<a id="topic-2.2.1.3-9"></a>

###### Malignant insulinoma: onset of hypoglycemia after a non-functioning tumor

> “In 16.1% of the cases, the hypoglycaemic syndrome occurred after 46 ± 35 months from the diagnosis of originally non-functioning NET, whereas in 83.9% of the cases it led to the diagnosis of NET, of which 42.3% with a mean diagnostic delay of 32.7 ± 39.8 months.”

Source: [Veltroni et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32061159/)

<a id="topic-2.2.1.3-10"></a>

###### Metastatic insulinoma: variable natural history in a National Institutes of Health series

> “The authors identified 10 patients with metastatic insulinoma.”
> “Second, four patients presented with metastatic disease to the liver, which appeared years after the initial diagnosis and presumed curative surgery.”
> “Finally, 9 of the 10 patients had a prolonged survival.”
> “The current study, as well as others, suggested that metastatic insulinoma may have a variable natural history.”

Source: [Hirshberg et al. (2005)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4136659/)

<a id="topic-2.2.1.3-11"></a>

###### Metastatic insulinoma: survival with multimodal treatment at a tertiary center

> “Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.”
> “Seven subjects died during follow-up. The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).”
> “This compares to previous reports of median survival of about 2 years.”
> “Seven subjects are alive 1.2-12.3 years after diagnosis. Hypoglycemia was well-controlled and did not cause the deaths.”

Source: [Masharani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954510/)

<a id="topic-2.2.1.3-12"></a>

###### NICTH: recovery and in-hospital mortality in a systematic review of published cases

> “Outcome data included tumour recurrence, hypoglycaemia and in‐hospital mortality.”
> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”
> “Most patients successfully recovered (77%); however, a significant mortality rate was identified (23%).”
> “Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).”
> “Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.3-13"></a>

###### Tumor hyperinsulinism: company characterization of morbidity and mortality

> “Resulting hypoglycemia is often severe and may have serious adverse outcomes”
> “High morbidity and mortality rates”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-2.2.1.4"></a>

##### 2.2.1.4 Pathophysiology

<a id="topic-2.2.1.4-1"></a>

###### Tumor hyperinsulinism: insulin receptor over-activation as described by the manufacturer

> “Severe, persistent, life-threatening complication of over activation of the insulin receptor”
> “Excessive secretion of insulin”
> “Produce and secrete insulin-like paraneoplastic substances such as IGF-2 that over activate the insulin receptor”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.4-2"></a>

###### Insulinoma: insulin secretion not suppressed during hypoglycemia

> “By definition, in endogenous hyperinsulinism, the insulin secretion does not decrease to very low levels when plasma glucose concentrations decrease to hypoglycemic levels”
> “Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.4-3"></a>

###### Insulinoma: somatic genetic and epigenetic changes

> “Despite a low tumor mutational burden, insulinomas are enriched for genetic mutations and copy number variants in epigenetic modifiers”
> “The predominant recurring genetic variant in up to 30% of insulinomas is an activating T372R mutation in the Yin Yang 1 (YY1) gene, which is absent in nonfunctioning panNEN”
> “YY1 is a transcriptional activator of the insulin gene. MEN1 mutations appear to be less common in insulinomas than nonfunctioning panNEN, but insulinomas do display loss of heterozygosity of the MEN1 region at chromosome 11q13.1 in 30% of cases”
> “Insulinomas are also associated with aberrant methylation patterns, including of the insulin promoter, where noncanonical transcription factors drive insulin expression”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.4-4"></a>

###### Aggressive (malignant) versus indolent insulinoma: pathologic and molecular features

> “Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, expression of ARX and alpha-1-antitrypsin and decreased or absent immunohistochemical expression of insulin, PDX1 and GLP-1R. Moreover, aggressive insulinomas often harbor ATRX or DAXX mutations, the alternative lengthening of telomeres phenotype and chromosomal instability.”
> “Aggressive insulinomas have similarities to normal alpha-cells and non-functional pancreatic neuroendocrine tumors, while indolent insulinomas remain closely related to normal beta-cells.”

Source: [Hackeng et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36779771/)

<a id="topic-2.2.1.4-5"></a>

###### Malignant versus benign insulinoma: hormone concentrations and tumor size in a single-center cohort

> “Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide. Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.4-6"></a>

###### Non-islet cell tumor hypoglycemia: tumor IGF-2 release with suppressed insulin, IGF-1, and growth hormone

> “Tumors of mesenchymal and epithelial origin produce IGF-2, which activates pathways in the tumors. In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.”
> “Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH. Complicating the pathophysiology are the IGF binding proteins (IGFBPs) that can bind IGF-2 and IGF-1, modifying hormone metabolism and action.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.4-7"></a>

###### Non-islet cell tumor hypoglycemia: incompletely processed big IGF-2 and its bioavailability

> “Post-translational modifications of prepro-IGF-2 occur in the Golgi apparatus, where an intermediate molecule comprising the mature IGF-2 domain combined with part of the E-domain is formed and secreted into circulation in small quantities.”
> “The expression of high levels of IGF-2 RNA in such tumors results from a loss of imprinting of parent alleles and abnormal activation of promoter regions of the IGF-2 gene.”
> “This leads to the production of large quantities of prepro-IGF-2, which oversaturates the prohormone convertase enzyme responsible for converting prepro-IGF-2 to mature IGF-2.”
> “Binary complexes, being smaller, can more easily permeate capillary membranes, resulting in higher bioavailability of IGF-2 and a greater potential for hypoglycemic action.”
> “The rise in IGF-1 levels suppresses growth hormone (GH) secretion by the pituitary gland, which in turn reduces the production of ALS and IGFBP-3 by the liver. This creates a vicious cycle that further favors the formation of binary complexes.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

<a id="topic-2.2.1.4-8"></a>

###### Non-islet cell tumor hypoglycemia: effects of IGF-2 on glucose uptake, hepatic glucose output, and glucagon

> “IGF-2 produced by tumor cells binds to IRs in skeletal muscle cells, leading to increased glucose uptake.”
> “In the liver, IGF-2 suppresses gluconeogenesis, glycogenolysis, ketogenesis, and the activity of glucose-6-phosphatase, thereby blocking hepatic glucose release.”
> “Additionally, IGF-2 binds to IGF-1 and IR receptors on pancreatic alpha cells, suppressing glucagon release and exacerbating hypoglycemia.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “IGF‐2 typically demonstrates weak affinity for insulin receptors under normal physiological conditions. However, abnormally elevated levels of IGF‐2 can result in sufficient stimulation of insulin receptors, potentially inducing a state of clinically significant hypoglycaemia.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.4-9"></a>

###### Non-islet cell tumor hypoglycemia: hypoinsulinemia and large tumor size in a Japanese series

> “The diameters of the tumors were more than 10 cm in 70% of the patients. Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

<a id="heading-2.2.1.5"></a>

##### 2.2.1.5 Diagnosis

<a id="topic-2.2.1.5-1"></a>

###### Whipple triad: diagnostic hallmark of a hypoglycemic disorder

> “The Whipple triad, named after the American surgeon Allen O. Whipple (1881-1963), is the diagnostic hallmark establishing the existence of a hypoglycemic disorder and has the following 3 features: (1) symptoms, signs, or both consistent with hypoglycemia; (2) low plasma glucose measured at the time of the symptoms and signs; and (3) relief of symptoms and signs when the glucose is raised to a normal level”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-2"></a>

###### Endocrine Society guideline: evaluation of adults with hypoglycemia

> “We recommend evaluation and management of hypoglycemia only in patients in whom Whipple's triad”
> “In patients suspected of having endogenous hyperinsulinism, measure plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and circulating oral hypoglycemic agents during an episode of hypoglycemia and measure insulin antibodies.”

Source: [Cryer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19088155/)

<a id="topic-2.2.1.5-3"></a>

###### Insulinoma: biochemical diagnostic criteria

> “Thus, in patients with insulinoma, plasma insulin, C-peptide, and proinsulin concentrations are inappropriately high in the setting of low fasting plasma glucose concentrations”
> “According to the most recent clinical practice guidelines, critical diagnostic findings are present when the confirmed fasting plasma glucose concentrations are preferably below 45 mg/dL (2.5 mmol/L) or below 55 mg/dL (3.0 mmol/L)”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-4"></a>

###### Insulinoma: corrected insulin, C-peptide, and proinsulin thresholds

> “plasma insulin concentrations of at least 3 μU/mL (18 pmol/L), plasma C-peptide concentrations of at least 0.6 ng/mL (0.2 nmol/L), and plasma proinsulin concentrations of at least 5.0 pmol/L”

Source: [Journal of Clinical Endocrinology and Metabolism insulinoma correction (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13271780/)

> “The sensitivity and specificity of the established diagnostic criteria using insulin, C-peptide, proinsulin, beta-hydroxybutyrate, and glucose response to iv glucagon were greater than 90% and greater than 70%, respectively.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

<a id="topic-2.2.1.5-5"></a>

###### Insulinoma: supervised prolonged fasting test

> “If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.”
> “Some authors have advocated shorter fasting tests”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “We identified 127 patients with insulinoma.”
> “The fast was terminated due to hypoglycemia in 44 patients (42.5%) by 12 h, 85 patients (66.9%) by 24 h, and 120 (94.5%) by 48 h.”
> “Thus, the 48-h fast should replace the 72-h fast in textbooks and hospital protocols as the new diagnostic standard.”

Source: [Hirshberg et al. (2000)](https://pubmed.ncbi.nlm.nih.gov/10999812/)

> “Sixty-five patients underwent a fasting test, aiming at a 24, 36, or 72-hour fasting time.”
> “were met in 92% of the tests, after a median fasting time of 14 (0, 36) hours.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

<a id="topic-2.2.1.5-6"></a>

###### Insulinoma: beta-hydroxybutyrate stopping criterion in the 72-hour fast

> “After the update, 50% (N = 15) ended for BHB >2.7 mmol/L, with an average fast duration of 49.7 hours (median 53 hours, IQR [39.1, 71.8], P = .03).”
> “All insulinoma cases (N = 7) developed hypoglycemia within 43 hours with BHB ≤1.2 mmol/L; no cases were missed.”

Source: [Lundholm et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40288609/)

<a id="topic-2.2.1.5-7"></a>

###### Insulinoma: localization imaging strategy

> “Localization of the insulinoma and exclusion or confirmation of metastatic disease by CT is still the preferred initial localization modality followed by EUS or magnetic resonance imaging (MRI) for indolent, localized insulinomas”
> “Glucagon-like peptide 1 receptor (GLP-1R) PET/CT or PET/MRI is a highly sensitive localization technique for seemingly occult, indolent, localized insulinomas and has become increasingly popular.”
> “Preoperative localization of nonmetastatic insulinomas is important and sometimes difficult, because approximately 30% of insulinomas are less than 10 mm in diameter.”
> “However, as opposed to localized indolent insulinomas, aggressive malignant insulinomas often lack the expression of the GLP-1R.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-8"></a>

###### Insulinoma: sensitivity and specificity of localization modalities across published studies

| Modality | Sensitivity | Specificity |
| --- | --- | --- |
| CT | “54%” | “75%” |
| MRI | “54%” | “65%” |
| EUS | “81%” | “90%” |
| ASVS | “93%” | “86%” |
| SSTR SPECT | “53%” | “50%” |
| SSTR PET | “39%” | “14%” |
| GLP-1R SPECT | “83%” | “40%” |
| GLP-1R PET | “87%” | “94%” |

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.5-9"></a>

###### Insulinoma: GLP-1 receptor PET/CT in a prospective multicenter comparison

> “Sixty-nine adults with biochemically proven adult endogenous hyperinsulinemic hypoglycemia underwent exendin PET/CT and current routine imaging.”
> “Based on clinical readings, the accuracy of exendin PET/CT (94.4%; 95% CI, 84.6%–98.8%) was greater than that of DOTA-SSA PET/CT (64.8%; 95% CI, 50.6%–77.3%), contrast-enhanced CT/contrast-enhanced diffusion-weighted imaging-MRI (83.3%; 95% CI, 70.7%–92.1%), and endoscopic ultrasound (82.8%; 95% CI, 64.1%–94.1%).”
> “In 13% of patients, a correct diagnosis was only reached after exendin PET/CT.”

Source: [Boss et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11619583/)

<a id="topic-2.2.1.5-10"></a>

###### Insulinoma: GLP-1 receptor SPECT/CT in a prospective multicenter study

> “For 23 assessable patients, (111)In-DTPA-exendin-4 SPECT/CT had a higher sensitivity (95% [95% CI 74-100]) than did CT/MRI (47% [27-68]; p=0.011).”
> “Seven patients (23%) were referred to surgery on the basis of (111)In-DTPA-exendin-4 imaging alone.”

Source: [Christ et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/24622317/)

<a id="topic-2.2.1.5-11"></a>

###### Insulinoma: preoperative localization over time in cohort studies

> “The overall imaging sensitivity improved from 39% in the 1980s to 98% in the 2000s”
> “The tumour was localized preoperatively in 59 (75%) of the patients.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “Although the rates of localization by noninvasive techniques remained static at approximately 75%, the addition of invasive modalities has resulted in successful preoperative localization in all patients in the past 10 yr.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

<a id="topic-2.2.1.5-12"></a>

###### Insulinoma: diagnostic delay and prior misdiagnosis

> “The median diagnostic delay was 13 months and did not change over the study period.”
> “Thirty-one of 79 patients were first examined for their symptoms by specialities other than endocrinology, most often by neurology, neurosurgery, or cardiology.”
> “The episodic symptoms were often interpreted as cerebrovascular disorders, epilepsy, or psychiatric disorders.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “The interval from the onset of symptoms to diagnosis ranged from 1 month to 30 years (median 24 months).”
> “Prior diagnoses included neurologic disorders (64%), especially seizure disorders (39%); 7 (12%) patients were treated with antiseizure medications.”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.5-13"></a>

###### Malignant insulinoma: biochemical and tumor-size features at diagnosis

> “Patients with malignant insulinoma presented with higher levels of insulin, proinsulin, and c-peptide.”
> “Malignant lesions were larger: 4.2 ± 3.2 vs 1.8 ± 0.8 cm in benign lesions, p < 0.01.”

Source: [Sada et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/32873371/)

<a id="topic-2.2.1.5-14"></a>

###### NICTH: biochemical pattern and IGF-2 to IGF-1 ratio

> “In a hypoglycemic patient with low insulin and C-peptide, a low β-hydroxybutyrate level suggests an agent mimicking insulin and is therefore an indication to measure IGF-I and IGF-II”
> “The typical pattern for NICTH on the above laboratory studies includes low glucose (serum glucose < 55 mg/dL) with simultaneous low insulin/proinsulin/C-peptide/β-hydroxybutyrate levels, and the absence of positive results on an oral hypoglycemic agent screen.”
> “This ratio may be an important screening tool for NICTH in cases of hypoglycemia”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

> “Typically, the elevated IGF-2 levels are associated with suppressed plasma levels of insulin, IGF-1, and GH.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

> “A ratio of IGF‐2 and IGF‐1 in a healthy individual is 3:1. A molar ratio larger than 10 in recurrent hypoglycaemia supports NICTH.”
> “an 88% positivity rate for IGF2:IGF1 ratio>10”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.1.5-15"></a>

###### NICTH: hypoinsulinemia and tumor size in a Japanese case series

> “Basal immunoreactive insulin (IRI) levels were less than 3 microU/dl in 79% of the patients.”
> “The diameters of the tumors were more than 10 cm in 70% of the patients.”
> “These data suggested that hypoinsulinemic hypoglycemia associated with the presence of a large tumor supports the diagnosis of IGF-II producing NICTH.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

<a id="topic-2.2.1.5-16"></a>

###### NICTH: test availability and tumor imaging

> “To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.”
> “If laboratory results suggest NICTH (eg, high IGF-II:IGF-I ratio and absence of evidence for hyperinsulinemia), a reasonable next step is cross-sectional imaging of the chest, abdomen, and pelvis to identify a tumor, given that the vast majority of reported cases of NICTH involve a tumor in one of these sites.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

> “Given the relative infrequency of testing for IGF‐1, IGF‐2 and pro‐IGF‐2 testing, the diagnosis of NICTH poses considerable challenges and is often overlooked, which may lead to significant clinical consequences.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="heading-2.2.1.6"></a>

##### 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

###### Neuroglycopenic symptoms: insulinoma

> “neuroglycopenic symptoms such as confusion, visual disturbances, or seizures may also occur. The latter may cause patients to be misdiagnosed with a psychiatric or neurological disorder.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “96% of the patients had neuroglycopenic symptoms, and 77% had autonomic symptoms.”
> “The most common presenting symptoms were confusion (86%), drowsiness (58%), and excessive sweating (57%).”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “All patients had neuroglycopenic symptoms including confusion (83%) and personality change or bizarre behavior (64%).”
> “Amnesia for hypoglycemia was common (41%).”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-2"></a>

###### Autonomic symptoms: insulinoma

> “In addition to the familiar hypoglycemic symptoms such as sweating, palpitations, nervousness, and feeling of hunger”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Autonomic symptoms (83%) were usually diaphoresis (69%) or tremulousness (24%).”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-3"></a>

###### Timing of symptoms: fasting and postprandial hypoglycemia in insulinoma

> “Symptoms occur mainly in the fasting state, but up to 20% of patients also described postprandial symptoms”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Hypoglycemia was reported solely in the fasting state in 73%, the fasting and postprandial state in 21%, and exclusively postprandially in 6%.”

Source: [Placzkowski et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19141587/)

> “The symptoms were usually progressive, provoked by fasting, and at worst, occurred daily or weekly.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “Food ingestion relieved symptoms in 71% of patients”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-4"></a>

###### Weight gain: insulinoma

> “Weight gain was documented in 56% of the patients, of whom one-third gained weight more than 10 kilograms.”

Source: [Peltola et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6218736/)

> “39% reported weight gain.”

Source: [Dizon et al. (1999)](https://pubmed.ncbi.nlm.nih.gov/10190379/)

<a id="topic-2.2.1.6-5"></a>

###### Tumor-related features: aggressive insulinoma

> “Aggressive insulinomas are characterized by rapid onset of symptoms, larger size, and expression of ARX and alpha-1-antitrypsin, and decreased or absent immunohistochemical expression of insulin, PDX1, and GLP-1R.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Patients with malignant insulinoma were younger (median, 55.5 vs 66.0 years, P < .001) and less likely to be female (55.9% vs 65.3%, P = .061) than patients with benign insulinoma.”

Source: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

<a id="topic-2.2.1.6-6"></a>

###### Adrenergic, cholinergic, and neuroglycopenic symptoms: tumor hyperinsulinism

> “The clinical manifestations of hypoglycemia are marked by adrenergic, cholinergic, and neuroglycopenic symptoms such as tremors, diaphoresis, confusion, seizures, and loss of consciousness, and may lead to life-threatening consequences”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.6-7"></a>

###### Neuroglycopenic symptoms: NICTH

> “Loss of consciousness and confusion were the most common features in the patients, present in 26.7% and 21%, respectively.”
> “Weight loss, dizziness and weakness were other relatively less common features.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “In paraneoplastic hypoglycemia, the symptoms predominantly manifest as neuroglycopenic, affecting cognitive function and mental status significantly.”
> “On the other hand, in cases of recurrent or gradual-onset hypoglycemia, autonomic symptoms like sweating and tremors may be less noticeable.”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

<a id="topic-2.2.1.6-8"></a>

###### Tumor-related symptoms and order of presentation: NICTH

> “Hypoglycemic attack was the onset of disease in 31 of 65 cases (48%), but the tumor was revealed prior to the occurrence of hypoglycemia in 34 cases (52%).”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Hypoglycaemia was identified as the presenting feature of NICT in 42% (98) of patients.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

> “Symptoms directly related to the tumor typically include weight loss, abdominal mass, pain, dyspnea, or incidental findings during routine examinations”

Source: [Karamanolis et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11342107/)

> “In a minority of patients, the tumors (hepatomas, fibromas, and fibrosarcomas are the most common among many) release into the circulation enough IGF-2-related peptides to mimic the fasting hypoglycemia characteristic of patients with insulin-producing islet-cell tumors.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="topic-2.2.1.6-9"></a>

###### Metabolic and somatic features: hypokalemia and acromegaloid changes in NICTH

> “Twenty-five of 47 (53%) patients had decreased serum potassium levels.”

Source: [Fukuda et al. (2006)](https://pubmed.ncbi.nlm.nih.gov/16860583/)

> “Rarely, markedly elevated IGF-2 levels produce somatic changes suggestive of acromegaly.”

Source: [Dynkevich et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23671155/)

<a id="heading-2.2.1.7"></a>

##### 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

###### Insulinoma: long-term morbidity compared with matched controls

> “The long-term incidence of atrial fibrillation (rate ratio (RR): 2.07 (95% CI: 1.02–4.22)), intestinal obstruction (18.65 (2.09–166.86)), and possibly breast (4.46 (1.29–15.39) and kidney cancers (RR not applicable) was increased among insulinoma patients vs controls, P < 0.05 for all comparisons.”
> “Endocrine disorders and pancreatic diseases were more frequent in the patients during the first year after insulinoma diagnosis, but not later on.”
> “The incidence of dementia or all mental and behavioural disorders did not significantly differ between the patients and the controls”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.7-2"></a>

###### Insulinoma: late surgical complications

> “Most cases of pancreatitis occurred as early postoperative complications, with a rate of 10% in the surgically treated patients, as described previously”
> “Intestinal obstruction occurred in 5% of the surgically treated patients, likely as a late postoperative complication of insulinoma surgery.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.7-3"></a>

###### Insulinoma: residual hypoglycemia and post-treatment diabetes in a Japanese nationwide survey

> “Post‐surgery residual hypoglycemia was found in eight patients: one had benign, five had malignant, and two had unknown histology.”
> “By contrast, post‐treatment diabetes mellitus was more prevalent and found in 25 (15.8%) patients who underwent pancreatectomy: 3.8% of those who had tumor enucleation, 21.3% of body and/or tail resection, 26.3% of pancreatoduodenectomy, and 100% of subtotal resection.”
> “In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.7-4"></a>

###### Insulinoma: neurological impairment and cognitive function

> “Even after undergoing these extensive treatments, neurological impairment still occurred in 22 (10.7%) patients with insulinoma: seven had dementia, seven had epilepsy and eight had other neurological deficits.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

> “Eighteen out of thirty-four patients (53%) with insulinoma were screened positive for cognitive impairment as defined by a MoCA score <26.”
> “The remaining ten patients with cognitive impairment showed improvements 1 year postoperatively, and seven patients recovered to normal cognitive function.”

Source: [Dai et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31292840/)

<a id="topic-2.2.1.7-5"></a>

###### Malignant insulinoma: morbidity of refractory hypoglycemia

> “Refractory hypoglycemia is common in malignant insulin-secreting tumors and is associated with substantial morbidity.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.7-6"></a>

###### NICTH: long-term morbidity

No evidence found.

Additional sources: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

<a id="heading-2.2.1.8"></a>

##### 2.2.1.8 Burden of Tumor hyperinsulinism

<a id="heading-2.2.1.8.1"></a>

###### 2.2.1.8.1 Humanistic Burden and Health-related Quality of Life

<a id="topic-2.2.1.8.1-1"></a>

###### Company description of the humanistic burden of tumor hyperinsulinism (insulinoma and NICTH)

> “Resulting hypoglycemia is often severe and may have serious adverse outcomes”
> “High morbidity and mortality rates”
> “Significant adverse impact on patient quality of life”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.8.1-2"></a>

###### Functional status and hospice consideration in refractory tumor hyperinsulinism (malignant insulin-secreting tumors)

> “current standard-of-care therapies to reduce hypoglycemia often fail to achieve sustained glycemic stability and are associated with high morbidity (hospitalization, poor functional status, etc.)”
> “Four of the 8 individuals had a baseline ECOG score of 3, 1 had an ECOG of 2, and 3 had an ECOG of 1.”
> “Two individuals were under hospice consideration at baseline due to refractory hypoglycemia, progressive disease, and lack of remaining tumor-directed treatment options.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.8.1-3"></a>

###### Impaired quality of life with residual hypoglycemia after insulinoma treatment (Japanese nationwide survey)

> “In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.8.1-4"></a>

###### Long-term 15D health-related quality of life after curative surgery for insulinoma (Finland)

> “The HRQoL of adults diagnosed with an insulinoma in Finland in 1980-2010 was studied with the 15D instrument, and the results were compared to those of an age- and gender-matched sample of the general population.”
> “Thirty-eight insulinoma patients participated in the HRQoL survey (response rate 75%).”
> “All had undergone surgery with a curative aim, a median of 13 (min 7, max 34) years before the survey.”
> “The insulinoma patients had a clinically importantly and statistically significantly better mean 15D score compared with the controls (0.930 ± 0.072 vs 0.903 ± 0.039, P = .046) and were significantly better off regarding mobility, usual activities and eating.”
> “In the long term, the overall HRQoL of insulinoma patients is slightly better than that of the general population.”

Source: [Peltola et al. (2021a)](https://pubmed.ncbi.nlm.nih.gov/32974918/)

<a id="topic-2.2.1.8.1-5"></a>

###### Health-related quality of life in non-islet cell tumor hypoglycemia

No evidence found.

<a id="heading-2.2.1.8.2"></a>

###### 2.2.1.8.2 Economic Burden and Healthcare Resource Utilization

<a id="topic-2.2.1.8.2-1"></a>

###### Company description of hospitalization and deferred tumor treatment in tumor hyperinsulinism

> “Frequent prolonged hospitalization”
> “Leads to frequent deferral of tumor treatment”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.1.8.2-2"></a>

###### Hospitalization and continuous parenteral dextrose among expanded access patients (company filing)

> “These patients have generally required continuous parenteral dextrose in order to prevent severe hypoglycemia and were typically hospitalized and in life-threatening or hospice-bound condition at the time of request.”
> “Further treatment with tumor-directed therapies (e.g., embolization, radiotherapy, chemotherapy) was often deferred as a result of debilitating hypoglycemia.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.1.8.2-3"></a>

###### Inpatient days and parenteral glucose support in refractory malignant insulin-secreting tumors

> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”
> “Two individuals initiated ersodetug prior to hospitalization, including one receiving continuous carbohydrate supplementation via home TPN.”
> “Supportive strategies such as frequent carbohydrate intake or continuous parenteral dextrose infusion are often required but are burdensome and do not provide durable control, and parenteral infusions may prevent hospital discharge.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.8.2-4"></a>

###### Hospital stay after surgical resection versus endoscopic ultrasound-guided ablation of sporadic insulinoma

> “Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001).”

Source: [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/)

<a id="topic-2.2.1.8.2-5"></a>

###### Postoperative length of stay after insulinoma resection (single center)

> “A retrospective analysis of 33 patients who had an insulinoma resected and who underwent routine postoperative monitoring of blood glucose”
> “The average postoperative length of hospital stay was 9 days”

Source: [Nockel et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8058619/)

<a id="topic-2.2.1.8.2-6"></a>

###### Admission for glucose monitoring around hepatic artery embolization of insulinoma liver metastases

> “The night before HAE, patients were admitted for blood glucose monitoring.”
> “Liver-directed therapies control tumor burden and address severe associated hypoglycemia symptoms, the latter of which require vigilance and careful meal timing on an outpatient basis.”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.1.8.2-7"></a>

###### Continuous intravenous support and cost of growth hormone therapy in non-islet cell tumor hypoglycemia (review)

> “However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.”
> “Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.”
> “Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases”
> “Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.1.8.2-8"></a>

###### Cost-of-illness or claims-based cost studies of insulinoma or NICTH

No evidence found.

<a id="heading-2.2.1.8.3"></a>

###### 2.2.1.8.3 Economic Impact of Tumor hyperinsulinism on Families

Not applicable.

<a id="heading-2.2.1.8.4"></a>

###### 2.2.1.8.4 Economic Impact of Diagnostic Testing

<a id="topic-2.2.1.8.4-1"></a>

###### Inpatient 72-hour fast for insulinoma: duration and cost (quality improvement report)

> “test for detecting insulinoma but imposes significant burdens on patients and expends hospital resources.”
> “The original protocol had an average fast duration of 57.6 hours (median 72 hours, IQR [49,72]).”
> “This reduced cumulative inpatient fasting by 376.5 hours and reduced medical costs.”
> “Adding a BHB >2.7 mmol/L stopping criterion reduced inpatient hospitalization time, medical costs, and patient burden without compromising insulinoma detection.”

Source: [Lundholm et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40288609/)

<a id="topic-2.2.1.8.4-2"></a>

###### Prolonged fasting test when hypoglycemia does not occur spontaneously (insulinoma)

> “If hypoglycemia does not occur spontaneously, a 72-hour prolonged fasting test should be performed and blood should be drawn for measurements of insulin, and pro-insulin, or C-peptide measurements if hypoglycemia occurs.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.1.8.4-3"></a>

###### Availability of big IGF-II measurement for NICTH diagnosis

> “To our knowledge, there is no commercially available assay for big IGF-II, and measurement of high molecular weight precursor forms of IGF-II must be done in a research laboratory setting at this time.”
> “Nevertheless, a widely available assay would assist all practitioners, especially those without access to a research laboratory.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.1.8.4-4"></a>

###### Cost of diagnostic testing for tumor hyperinsulinism

No evidence found.

<a id="heading-2.2.2"></a>

#### 2.2.2 Approaches to Treatment

<a id="heading-2.2.2.1"></a>

##### 2.2.2.1 Current Treatment Options and Standard of Care

<a id="heading-2.2.2.1.1"></a>

###### 2.2.2.1.1 Surgical Resection

<a id="topic-2.2.2.1.1-1"></a>

###### Surgery for localized insulinoma: ENETS guidance

> “As distinct from asymptomatic patients with NF-Pan-NET ≤2 cm, active surveillance is not appropriate for patients with insulinomas due to the presence of functioning symptoms.”
> “Surgical resection is the gold standard treatment for localised insulinomas.”
> “The main advantage of parenchyma-sparing over formal resections is represented by the excellent long-term functional outcomes. On the other hand, a major challenge is still represented by the high morbidity rate, mainly related to the risk of pancreatic fistula.”
> “Parenchyma-sparing pancreatic resections, including enucleation and central pancreatectomy, should be proposed as a first-line surgical strategy in patients with insulinoma [2b, A].”
> “A minimally invasive approach should be always considered, when technically feasible, for patients with preoperatively localised insulinomas [2a, A].”
> “Localised low-grade insulinomas are cured by radical surgery and do not require long-term follow-up [3, A].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.1-2"></a>

###### Cytoreductive surgery for advanced functioning tumors including insulinoma: ENETS guidance

> “Strategies that result in a reduction of tumour bulk generally also significantly reduce patient hormonal symptoms [2b, B]. Cytoreductive surgery can be considered for patients with functioning tumours when ≥70%–90% of visible disease can be debulked.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.1-3"></a>

###### Surgery and debulking for functioning pancreatic tumors including insulinoma: ESMO guideline

> “Moreover, surgery is mandatory in the presence of functioning Pan-NETs irrespective of tumour size.”
> “Functioning Pan-NETs ≤2 cm (e.g. insulinomas) represent ideal lesions to be enucleated, given that they are safely distant from the main pancreatic duct.”
> “Patients with high tumour burden of functioning Pan-NETs may benefit from debulking surgery [e.g. insulinoma, vasoactive intestinal peptide (VIP)oma], and surgery is generally recommended for this indication [IV, B].”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.1-4"></a>

###### Resection of localized insulinoma: NANETS surgical guideline

> “Resection of a localized insulinoma results in a 98% biochemical cure rate with a 6% chance of recurrence at 10 years.”
> “In the case of insulinoma, the morbidity associated with an extensive pancreatic mobilization and 10% risk of non-palpable or non-visible tumors outweigh the low-risk of malignancy.”
> “Therefore, surgical exploration or blind resection of the tail of the pancreas are not recommended.”
> “Patients with a localized, biochemically confirmed, functional PNET should be resected because clinical syndromes associated with each are significant, even when small in size. Furthermore, with the exception of insulinoma, the majority have significant malignant potential.”
> “Criteria for selection of patients for enucleation have not been defined, but expert opinion suggests that enucleation should be reserved for smaller tumors, those more likely to display benign behavior (such as insulinomas or NF-PNETs <2 cm), and that are located >2–3 mm from the main pancreatic duct.”

Source: [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/)

<a id="topic-2.2.2.1.1-5"></a>

###### Surgery for benign and malignant insulinoma: JNETS guideline

> “Surgery is generally recommended for insulinomas; when indicated, a minimally invasive approach is preferable [40, 41]. Pancreatectomy with lymphadenectomy is recommended for malignant insulinomas [42].”

Source: [Ito et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8531106/)

<a id="topic-2.2.2.1.1-6"></a>

###### Curative resection and debulking for insulinoma: clinical review

> “For single solitary insulinomas, curative surgical excision remains the treatment of choice. However, it should be performed only when the diagnosis is certain and by a surgeon who is skilled in pancreatic surgery.”
> “Complications following pancreas resection include postoperative pancreatic fistula, postpancreatectomy hemorrhage, and delayed gastric emptying together with exocrine and endocrine pancreatic insufficiency.”
> “In aggressive malignant cases, debulking of the panNEN, including locoregional lymph nodes can be considered on a case-by-case basis, particularly in an attempt to control the endogenous hyperinsulinemic hypoglycemia (54, 103, 118).”
> “If more than 90% of tumor load can be resected, palliative surgery can also be considered.”
> “However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment (54).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.1-7"></a>

###### Outcomes after enucleation and pancreatic resection of insulinoma in 198 patients

> “A total of 198 patients (58.5% women; median age, 48 years) were identified.”
> “Surgical procedures included 106 enucleations (54%) and 92 pancreatic resections (46%). Mortality was nil. Rate of clinically significant pancreatic fistula was 18%. Enucleations had a higher reoperation rate compared with pancreatic resections (8.5% vs 1%; P = .02).”
> “Median follow-up was 65 months. Six patients (3%; 5 patients had neuroendocrine tumors grade G2) developed tumor recurrence. Four patients (2%) died of disease. New exocrine (1.5%) and endocrine (4%) insufficiencies were associated only with pancreatic resections.”

Source: [Crippa et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22430908/)

<a id="topic-2.2.2.1.1-8"></a>

###### Perioperative morbidity of sporadic insulinoma resection over three decades

> “Eighty patients underwent surgery for sporadic pancreatic insulinoma, 50 of which were female (62%), with a median age of 50 (36-70) years.”
> “The mortality rate was 6% (n = 5), with a morbidity rate of 72%, including 24 severe complications (30%) and 35 pancreatic fistulas (44%). No differences were found between formal pancreatectomy and PSP in terms of postoperative outcome procedures. The surgery was curative in all the patients.”

Source: [de Carbonnières et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33975801/)

<a id="topic-2.2.2.1.1-9"></a>

###### Long-term cure after insulinoma resection at a referral center over two decades

> “Sixty-one of 202 operated patients with pNEN had an insulinoma, 37 (61%) in group 1 and 24 (39%) in group 2.”
> “Enucleation was the most frequently performed operation (31 of 61, 51%), followed by distal resection (15 of 61, 25%) without significant differences between groups 1 and 2. The rate of relevant postoperative complications was not different between groups 1 and 2 (24% vs. 21%, p = 0.99). Two patients with benign insulinoma (1 out of each group) experienced disease recurrence and underwent a second resection. After a median follow-up of 134 (1–249) months, however, all 57 (100%) patients with benign insulinoma and 3 out of 4 patients with malignant insulinoma had no evidence of disease.”

Source: [Wiese et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10310606/)

<a id="topic-2.2.2.1.1-10"></a>

###### Minimally invasive versus open resection of insulinoma

> “28 patients (37.8%) underwent an open approach, and 46 patients (62.2%) underwent an MIS approach.”
> “Resection done by a MIS approach was associated with shorter length of stay (5.0 vs. 6.5 days, p = 0.011), fewer grade III/IV surgical complications (19.6% vs. 32.1%, p = 0.15), lower 30-day readmission rates (17.4% vs. 42.9%, p = 0.034), and no cases of incisional hernia (0% vs. 14.3%%, p = 0.018) within two years post-operatively. The difference in local recurrence rates was not statistically significant (4.3% vs. 3.6%, p = 1).”

Source: [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42362418/)

<a id="topic-2.2.2.1.1-11"></a>

###### Long-term recurrence after insulinoma resection by MEN1 status

> “The risk of recurrence was greater among patients with MEN I (21% at 10 and 20 years) than in those without MEN I (5% at 10 years and 7% at 20 years).”

Source: [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/)

<a id="topic-2.2.2.1.1-12"></a>

###### Survival with and without surgery in malignant insulinoma

> “A total of 121 patients were identified.”
> “Surgical resection was performed in 64% of patients.”
> “5-year OS was 84% and 14% for the surgery and no-surgery groups, respectively, p < 0.001.”
> “On multivariable analysis, surgical resection, male sex, and absence of metastatic disease were associated with greater overall and cancer-specific survival”

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/)

<a id="topic-2.2.2.1.1-13"></a>

###### Surgical resection for NICTH: clinical review

> “Once NICTH is identified and a primary tumor is found, the mainstay of treatment is surgical resection, which is curative for hypoglycemia if resection is complete (63–69). Resolution of hypoglycemia has also been described in cases of subtotal resection (70). In rare instances, hypoglycemia recurs with tumor recurrence after what was thought to be complete resection (71, 72). However, in many cases, total resection is either delayed or not feasible.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.1-14"></a>

###### Surgical removal and recovery in IGF-2-mediated NICTH: systematic review of published cases

> “Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.”
> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.2.1.1-15"></a>

###### Surgery among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- |
| Surgery | “95 (55.2%)” | “15 (29.4%)” | “.002” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="heading-2.2.2.1.2"></a>

###### 2.2.2.1.2 Endoscopic Ultrasound-guided Ablation

<a id="topic-2.2.2.1.2-1"></a>

###### Radiofrequency ablation for small localized insulinoma: ENETS guidance

> “EUS-guided radiofrequency ablation (EUS-RFA) is a novel technique able to induce necrosis of small pancreatic lesions. EUS-RFA seems a safe and effective treatment option for small (≤2 cm) localised insulinomas, especially in patients considered unfit for surgery.”
> “In this regard, recent retrospective series and meta-analyses have shown a high clinical success rate (86%–96%), reporting only minor treatment-related adverse events”
> “However, further data in terms of long-term survival and recurrence rate are needed before proposing this procedure routinely in patients with small insulinomas, and these interventions should be confined to expert centres.”
> “EUS-RFA might be considered as treatment option in patients with small (≤2 cm) localised insulinomas considered as unfit for surgery [2a, C].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.2-2"></a>

###### Nonsurgical ablation for localized insulinoma: clinical review

> “Nonsurgical therapy can be considered in patients who either have comorbidities precluding resection or do not want to undergo resection after being appropriately counseled about therapeutic options. In selected cases, curative EUS-guided radiofrequency ablation of a localized insulinoma can be feasible and safe, although long-term data are pending (19, 54, 103, 109–112).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.2-3"></a>

###### Radiofrequency ablation versus surgery for insulinoma: propensity-matched multicenter comparison

> “Patients with sporadic PI who underwent EUS-RFA at 23 centers or surgical resection at 8 high-volume pancreatic surgery institutions between 2014 and 2022 were retrospectively identified and outcomes compared using a propensity-matching analysis.”
> “Using propensity score matching, 89 patients were allocated in each group (1:1), and were evenly distributed in terms of age, sex, Charlson comorbidity index, American Society of Anesthesiologists score, body mass index, distance between lesion and main pancreatic duct, lesion site, size, and grade. Adverse event (AE) rate was 18.0% and 61.8% after EUS-RFA and surgery, respectively (P < .001). No severe AEs were observed in the EUS-RFA group compared with 15.7% after surgery (P < .0001). Clinical efficacy was 100% after surgery and 95.5% after EUS-RFA (P = .160).”
> “However, the mean duration of follow-up time was shorter in the EUS-RFA group (median, 23 months; interquartile range, 14-31 months vs 37 months; interquartile range, 17.5-67 months in the surgical group; P < .0001). Hospital stay was significantly longer in the surgical group (11.1 ± 9.7 vs 3.0 ± 2.5 days in the EUS-RFA group; P < .0001). Fifteen lesions (16.9%) recurred after EUS-RFA and underwent a successful repeat EUS-RFA (11 patients) or surgical resection (4 patients).”

Source: [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/)

<a id="topic-2.2.2.1.2-4"></a>

###### Prospective multicenter radiofrequency ablation including 30 insulinomas

> “During the study period, a total of 60 patients were enrolled, 30 with insulinomas and 30 with NF-PanNETs (mean lesion size 14.5 ± 4.5 mm). In 78.3% of patients, a single RFA session was performed. Overall, AEs occurred in nine of 60 patients (15%), in four patients (13.3%) with insulinomas and in five (16.7%) with NF-PanNETs, with only one severe AE. Complete insulin hypersecretion symptom resolution was obtained in 29 of 30 patients (96.7%) with insulinomas”
> “Eight AEs occurred peri-procedurally, including five cases of mild acute pancreatitis all managed conservatively without prolongation of hospital stay or occurrence of any sequelae.”

Source: [Rizzatti et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12550746/)

<a id="topic-2.2.2.1.2-5"></a>

###### Ethanol and radiofrequency ablation of insulinoma: systematic review of published cases

> “In total, we identified 35 case reports and case series describing 75 patients with insulinomas treatment with EUS-guided ablation. Twenty-seven patients were treated with EUS-RFA, 47 patients with EUS-EA, and 1 patient received EUS-EA and EUS-RFA in the same session.”
> “The clinical success rate for EUS-guided ablation techniques was 98.5%.”
> “There were eleven adverse events: seven abdominal pain, two mild acute pancreatitis, one necrotising acute pancreatitis and one local hematoma. All patients recovered, and there were no periprocedural deaths.”

Source: [El Sayed et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8606734/)

<a id="topic-2.2.2.1.2-6"></a>

###### Ethanol ablation versus surgery for insulinoma: single-center comparison

> “Of these, 9 patients were treated with EUS-guided ethanol injection and 24 underwent pancreatic surgery.”
> “The lowest glucose values were similar between groups before (ethanol: 2.09±0.17 mmol/l vs. surgery: 1.81±0.08, p=0.158) and after (4.95±0.74 vs. 5.41±0.28, p=0.581) the respective treatments. Complications occurred more frequently in the surgery group (11 % vs. 54 %, p=0.026). One patient after prior partial pancreatectomy died postoperatively. The hospitalization time was significantly shorter in the ethanol group (4.78±0.78 days vs. 19.88±4.07, p<0.001).”

Source: [Jürgensen et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/37931914/)

<a id="topic-2.2.2.1.2-7"></a>

###### Ongoing randomized trial of radiofrequency ablation versus surgery for insulinoma

> “EUS-RFA Versus Surgery for Pancreatic Insulinoma (ERASIN-RCT)”
> “The goal of this muticentre randomized controlled trial is to compare endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA) with surgery for treatment of pancreatic insulinoma.”
> “Patients will be randomized to undergo EUS-RFA or surgical resection.”

Source: [ClinicalTrials.gov NCT05735912](https://clinicaltrials.gov/study/NCT05735912)

<a id="heading-2.2.2.1.3"></a>

###### 2.2.2.1.3 Dietary Measures and Parenteral Glucose or Glucagon

<a id="topic-2.2.2.1.3-1"></a>

###### Diet, glucose infusion, glucose monitoring, and glucagon for insulinoma: ENETS guidance

> “In the control of insulinoma-related hypoglycaemia, fractioned diet including complex carbohydrates with slow absorption is the cornerstone to avoid prolonged fasting [5, A]. Simple carbohydrates as well as glucose infusion are required in hypoglycaemic events.”
> “A CGMS could be a very useful tool in patients with insulinoma to early recognise a hypoglycaemic event and prevent severe complications. Furthermore, it is also possible to connect an infusion pump automatically administering glucose as required.”
> “To manage acute episodes of hypoglycaemia, glucagon therapy is now available in different formulations (intramuscular, subcutaneous, intranasal). The intranasal spray formulation is easily administered and rapidly effective in patients with severe hypoglycaemic events, especially when an intravenous glucose infusion is not available”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.3-2"></a>

###### Dietary measures, tube feeding, and intravenous glucose for insulinoma: clinical review

> “Dietary/glucose: regular meals or snacks rich in slow carbohydrates, also ante noctem, are generally recommended (Fig. 3). The inclusion of a bedtime or late night meal is sufficient in most patients, but nocturnal tube feeding might be required to avoid nocturnal hypoglycemia in severely symptomatic patients. IV glucose administered via a central IV indwelling catheter might be needed for the control of severe recurrent hypoglycemia.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.3-3"></a>

###### Glucagon contraindication in insulinoma and other label limits: glucagon prescribing information

> “GVOKE is indicated for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients aged 2 years and older with diabetes.”
> “Insulinoma because of the risk of hypoglycemia [see Warnings and Precautions (5.2)]”
> “In patients with insulinoma, administration of glucagon may produce an initial increase in blood glucose; however, glucagon administration may directly or indirectly (through an initial rise in blood glucose) stimulate exaggerated insulin release from an insulinoma and cause hypoglycemia. GVOKE and GVOKE VialDx are contraindicated in patients with insulinoma [see Contraindications (4)].”
> “Patients with insufficient hepatic stores of glycogen may not respond to GVOKE for the treatment of severe hypoglycemia [see Clinical Pharmacology (12.2)]. Insufficient hepatic stores of glycogen may be present in conditions such as states of starvation, or in patients with adrenal insufficiency or chronic hypoglycemia.”
> “GVOKE and GVOKE VialDx are not approved for continuous infusion.”

Source: [Gvoke prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212097s012lbl.pdf)

<a id="topic-2.2.2.1.3-4"></a>

###### Continuous glucagon infusion for insulinoma and NICTH with liver metastases

> “Three patients had an insulinoma and four had non-islet cell tumor hypoglycemia (NICTH) due to hepatocellular carcinoma, colon carcinoma, meningeal sarcoma, and hemangiopericytoma, respectively. All of the patients had liver metastases.”
> “All patients with insulinoma responded to glucagon with a rise in blood serum glucose levels, indicating adequate glycogen stores. The four patients with NICTH had mixed responses: in two patients, the response suggested that hypoglycemia was due to an insulin-like tumor product; glucose levels did not rise in the other two cases, indicating that hypoglycemia was due to poor hepatic glycogen reserve/liver failure. In all cases, a glycemic response to glucagon predicted good response to long term treatment with glucagon (0.06-0.3 mg/hour, via intravenous infusion pump).”

Source: [Hoff and Vassilopoulou-Sellin (1998)](https://pubmed.ncbi.nlm.nih.gov/9554538/)

<a id="topic-2.2.2.1.3-5"></a>

###### Glucose, nutrition, and glucagon infusion for NICTH: clinical review

> “Initial treatment of hypoglycemia is accomplished by oral glucose and/or iv glucose- or dextrose-containing fluids as necessary. In many cases, this suffices to avoid further hypoglycemia (47, 55, 61, 62).”
> “However, when prompt resection is not feasible, iv glucose or dextrose often does not suffice to prevent hypoglycemia.”
> “Continuous glucagon infusion can be successful if the patient has a positive response to a glucagon stimulation test, and parenteral nutrition may allow higher glucose delivery, but both are limited by the need for continuous iv infusion.”
> “However, the use of partial parenteral nutrition or total parenteral nutrition is not a desirable long-term strategy given the necessity of long-term venous access with its inherent risks of complications and concomitant risks of bloodstream infections, liver toxicity, and electrolyte imbalances, not to mention cost (84).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="heading-2.2.2.1.4"></a>

###### 2.2.2.1.4 Diazoxide

<a id="topic-2.2.2.1.4-1"></a>

###### First-line medical therapy for advanced insulinoma: ENETS guidance

> “First-line medical therapy for advanced insulinoma consists of diazoxide (50–600 mg daily).”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.4-2"></a>

###### Diazoxide in metastatic insulinoma: ESMO guideline

> “Diazoxide is of value in metastatic insulinoma, as it inhibits the secretion of insulin by tumour cells”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.4-3"></a>

###### Preoperative control of insulinoma hypoglycemia with diazoxide: NANETS surgical guideline

> “Treatment of insulinoma relies on dietary changes as well as pharmacotherapy with diazoxide that can control hypoglycemia in 50–60% of cases.”

Source: [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/)

<a id="topic-2.2.2.1.4-4"></a>

###### Dosing and adverse effects of diazoxide in insulinoma: clinical review

> “Diazoxide is a nondiuretic benzothiadiazide vasodilator also known to control insulin secretion by blocking the adenosine triphosphate-dependent potassium channels of the pancreatic β cells (75).”
> “Generally, doses between 300 and 900 mg per day, usually divided into 3 equal and increasing doses every 8 hours, are rapidly successful in reversing hypoglycemia. The most frequent dose-limiting side effects of diazoxide occurring in up to 80% are fluid retention and edema, palpitations, nausea, anorexia, and hirsutism in female patients. Combination with a thiazide diuretic is generally recommended to prevent fluid retention, edema, and severe weight gain (7, 70, 78–80).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.4-5"></a>

###### Indication, dosing, warnings, and adverse reactions: diazoxide prescribing information

> “PROGLYCEM is indicated for the management of hypoglycemia due to hyperinsulinism associated with the following conditions: • Adults: Inoperable islet cell adenoma or carcinoma, or extrapancreatic malignancy.”
> “PROGLYCEM may be used preoperatively as a temporary measure, and postoperatively, if hypoglycemia persists.”
> “When other specific medical therapy or surgical management either has been unsuccessful or is not feasible, treatment with PROGLYCEM should be considered.”
> “Adults and children: The recommended starting dosage is 3 mg/kg/day, administered orally, divided into 3 equal doses every 8 hours or 2 equal doses every 12 hours. The dosage may be titrated to a maximum of 8 mg/kg/day. Patients with refractory hypoglycemia may require higher dosages.”
> “If administration of PROGLYCEM is not effective after 2 or 3 weeks, discontinue PROGLYCEM.”
> “The antidiuretic property of diazoxide may lead to significant fluid retention. In patients with compromised cardiac reserve, fluid retention may precipitate congestive heart failure.”
> “Ketoacidosis and nonketotic hyperosmolar coma have been reported in patients treated with PROGLYCEM, usually during intercurrent illness.”
> “Hirsutism of the lanugo type, mainly on the forehead, back and limbs, occurs most commonly in children and women and may be cosmetically unacceptable.”
> “Thrombocytopenia with or without purpura may require discontinuation of PROGLYCEM.”

Source: [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf)

<a id="topic-2.2.2.1.4-6"></a>

###### Long-term diazoxide in 40 patients with insulinoma: national survey

> “A survey of UK patients receiving the drug diazoxide, revealed 40 patients with insulinoma on this treatment.”
> “Duration of treatment was 7 +/- 6 years (range 1-22). Most (55%) patients were treated with diazoxide because of tumour non-localisation (including failed previous surgery). Metastatic disease (20%) and poor surgical risk (10%) were other indications. Side-effects (notably fluid retention and hirsutism) were common (47%) but not troublesome. Treatment was highly effective--59% were symptom free and 38% had only occasional symptoms. Only one patient had frequent hypoglycaemia despite treatment.”

Source: [Gill et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431498/)

<a id="topic-2.2.2.1.4-7"></a>

###### Diazoxide response and adverse effects in 20 patients with insulinoma

> “We retrospectively evaluated the medical records of 20 patients with insulinoma including 4 malignant cases.”
> “Diazoxide was effective and ineffective in each 9 patients, respectively. In other 2 cases, the efficacy could not be determined. In the effective group, all patients had benign insulinoma.”
> “Fluid retention was observed more frequently in females than in males (p = 0.025). Five patients displayed unacceptable thrombocytopenia within a few weeks after the administration of diazoxide.”

Source: [Niitsu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30504655/)

<a id="topic-2.2.2.1.4-8"></a>

###### Edema and heart failure with diazoxide in inoperable insulinoma

> “Herein, we report the results of our retrospective clinical record review of 6 Japanese patients (3 females and 3 males, ranging in age from 58 to 91 years) with hyperinsulinemic hypoglycemia and inoperable insulinoma treated with diazoxide. Diazoxide improved control of hypoglycemic symptoms and maintained normoglycemia in 5 of the 6 patients, and was ineffective in one patient. Surprisingly, although all 6 patients received diazoxide according to the treatment strategy recommended in Western patients, 5 of the 6 patients developed edema and two developed congestive heart failure.”

Source: [Komatsu et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26598136/)

<a id="topic-2.2.2.1.4-9"></a>

###### Diazoxide in NICTH: clinical review

> “Diazoxide and octreotide have no role in NICTH.”
> “Use in NICTH was not found to be successful in any case we reviewed (33, 36, 41, 53, 90). Additionally, use is often limited by fluid retention and edema (41).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.4-10"></a>

###### Diazoxide among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- | --- |
| Diazoxide | “16 (6.9%)” | “10 (5.8%)” | “6 (11.8%)” | “.25” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Halfdanarson et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32675783/)

<a id="heading-2.2.2.1.5"></a>

###### 2.2.2.1.5 Somatostatin Analogs

<a id="topic-2.2.2.1.5-1"></a>

###### Octreotide test, long-acting analogs, and off-label pasireotide for insulinoma: ENETS guidance

> “SSA can reduce insulin levels and prevent hypoglycaemic episodes in patients with advanced insulinomas.”
> “As SSA also decrease glucagon secretion and SSTR expression can be limited in insulinomas, which could paradoxically aggravate hypoglycaemia, a trial with short-acting octreotide under close monitoring of glucose levels is advised [5, D]. After demonstration of a positive effect on glucose levels, long-acting release (LAR) octreotide or lanreotide can be initiated. In cases with advanced insulinoma with hypoglycaemia refractory to octreotide or lanreotide, the pan-somatostatin receptor-targeting pasireotide can be tried off-label.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.5-2"></a>

###### Risk of worsening hypoglycemia in metastatic insulinoma: ESMO guideline

> “SSA should be used under surveillance for the risk of worsening hypoglycaemia.”

Source: [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="topic-2.2.2.1.5-3"></a>

###### Receptor expression, octreotide challenge, and pasireotide in insulinoma: clinical review

> “Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas (81).”
> “SRLs can adequately suppress the pathologic insulin hypersecretion in patients with insulinomas that express SSTR2 (17, 70, 81, 82). A challenge with subcutaneous administration of the short-acting SRL octreotide, is generally recommended before switching to a long-acting formulation. This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression (81–84).”
> “In Cushing disease, acromegaly and in phase 2-3 studies in NET (including panNET), hyperglycemia (79%), and type 2 diabetes were important side effects observed with pasireotide because of its inhibitory effects on incretin release (86–92). However, until now, pasireotide has not been approved for the treatment of panNET. Anecdotal reports show successful control with pasireotide of hypoglycemia in patients with insulinoma (75, 93–97).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.5-4"></a>

###### Octreotide response by somatostatin receptor subtype in insulinoma

> “Octreotide was effective on hypoglycaemia in 10/17 patients. Octreoscan scintigraphy detected 4/17 insulinomas. sst2A receptor was detected in 7/17 insulinomas and sst5 in 15/17 insulinomas.”
> “Octreotide is an effective treatment of hypoglycaemia in more than 50% of patients with insulinoma. Detection of responsive patients was better based on a positive short test with subcutaneous octreotide than on the results of Octreoscan scintigraphy.”

Source: [Vezzosi et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15879362/)

<a id="topic-2.2.2.1.5-5"></a>

###### Long-term octreotide in endogenous hyperinsulinism not treated by surgery

> “Reasons for not undergoing surgery were: refusal (n = 3), old age with multiple diseases (n = 5), unlocalized insulinomas (n = 2), malignant unresectable insulinomas (n = 5), multiple insulinomas (n = 3) and diffuse beta-cell disease (n = 3). Hypoglycaemia was responsive to octreotide in 14 of the 21 patients.”
> “Subcutaneous octreotide treatment was prolonged for > 6 months (7-144 months, 67 +/- 47 months) in 11 responsive patients. No tachyphylaxis was observed. However, the octreotide dose had to be increased in two patients after 3 and 18 months, respectively. Only one patient suffered from symptomatic biliary lithiasis after 3 years of treatment.”

Source: [Vezzosi et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18031316/)

<a id="topic-2.2.2.1.5-6"></a>

###### Pasireotide for insulinoma-associated hypoglycemia: systematic review of published cases

> “Of 490 identified studies, 137 were reviewed, and 17 cases from 13 studies met the inclusion criteria.”
> “Pasireotide was never the initial treatment. The most common doses were 40 to 60 mg/month for pasireotide long-acting release and 0.6 mg/12 h for short-acting pasireotide. Six patients (35%) showed no improvement, 4 (23%) had partial improvement, and 7 (41%) had complete resolution. Patients with aggressive insulinomas had a lower response rate, with 55% showing no improvement compared to 16% in indolent cases. Larger tumors were significantly associated with poorer response (P = .043). Hyperglycemia was the most common side effect (n = 3).”

Source: [Vega-Beyhart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40165498/)

<a id="topic-2.2.2.1.5-7"></a>

###### Octreotide indications and glucose warning: octreotide long-acting prescribing information

> “SANDOSTATIN LAR DEPOT is a somatostatin analogue indicated for: Treatment in patients who have responded to and tolerated Sandostatin Injection subcutaneous injection for: • Acromegaly (1.1) • Severe diarrhea/flushing episodes associated with metastatic carcinoid tumors (1.2) • Profuse watery diarrhea associated with Vasoactive Intestinal Peptide (VIP) secreting tumors (1.3)”
> “Octreotide alters the balance between the counter-regulatory hormones, insulin, glucagon, and growth hormone (GH), which may result in hypoglycemia or hyperglycemia. Blood glucose levels should be monitored when SANDOSTATIN LAR DEPOT treatment is initiated, or when the dose is altered.”

Source: [Sandostatin LAR Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf)

<a id="topic-2.2.2.1.5-8"></a>

###### Lanreotide antitumor indication and glucose warning: lanreotide prescribing information

> “SOMATULINE DEPOT is indicated for the treatment of adult patients with unresectable, well or moderately differentiated, locally advanced or metastatic gastroenteropancreatic neuroendocrine tumors (GEP-NETs) to improve progression-free survival.”
> “Pharmacological studies in animals and humans show that lanreotide, like somatostatin and other somatostatin analogs, inhibits the secretion of insulin and glucagon. Hence, patients treated with SOMATULINE DEPOT may experience hypoglycemia or hyperglycemia.”

Source: [Somatuline Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022074s032lbl.pdf)

<a id="topic-2.2.2.1.5-9"></a>

###### Pasireotide indication and hyperglycemia warning: pasireotide prescribing information

> “SIGNIFOR is indicated for the treatment of adult patients with Cushing’s disease for whom pituitary surgery is not an option or has not been curative.”
> “Blood glucose elevations have been seen in healthy volunteers and patients treated with SIGNIFOR.”
> “Nearly all patients in the study, including those with normal glucose status at baseline, pre-diabetes, and diabetes, developed worsening glycemia in the first two weeks of treatment.”

Source: [Signifor prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/200677s012lbl.pdf)

<a id="topic-2.2.2.1.5-10"></a>

###### Octreotide in NICTH: clinical review

> “Diazoxide and octreotide have no role in NICTH.”
> “Octreotide, a nonspecific somatostatin analog, has been used unsuccessfully in multiple cases (39, 91).”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.5-11"></a>

###### Octreotide among recovered and deceased patients with IGF-2-mediated NICTH

| Treatment | All cases | Recovered (n = 172) | Died (n = 51) | p-value |
| --- | --- | --- | --- | --- |
| Octreotide | “18 (7.7%)” | “9 (5.2%)” | “9 (17.6%)” | “.01” |

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

Additional sources: [Hendren et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29055143/)

<a id="heading-2.2.2.1.6"></a>

###### 2.2.2.1.6 mTOR Inhibitors

<a id="topic-2.2.2.1.6-1"></a>

###### Everolimus for hypoglycemia refractory to somatostatin analogs in advanced insulinoma: ENETS 2023 guidance

> “Everolimus is registered for progressive advanced Pan-NET and decreases insulin secretion and action.”
> “In a retrospective, multicentre series 11 out of 12 patients demonstrated swift disappearance of hypoglycaemic symptoms with a median symptom-free period of 6.5 months, although tolerance was limited.”
> “Consequently, both PRRT with 177Lu-DOTATATE and everolimus can be considered in advanced insulinoma cases with hypoglycaemia refractory to SSA, especially in those cases with concurrent progressive disease [4, C].”
> “PRRT, chemotherapy, everolimus or sunitinib should generally be reserved for SSA-refractory cases [4, B].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.6-2"></a>

###### Everolimus: approval status, hyperglycemic effect, and adverse effects in insulinoma

> “The drug is currently approved for the treatment of adult patients with advanced, progressive, and both functioning and nonfunctioning well-differentiated panNET”
> “The hyperglycemic effect of everolimus (and other mTOR inhibitors) is, therefore, a welcome side effect in the antiproliferative treatment of insulinomas”
> “Other major adverse effects of everolimus include skin rash, stomatitis, fatigue, gastrointestinal upset, pneumonitis, anemia, and opportunistic infections”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Furthermore, everolimus has been shown to suppress insulin secretion via inhibition of the mTORC1/S6K signalling pathway causing a reduction in hypoglycaemia in patients with advanced insulinomas”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.6-3"></a>

###### Everolimus in metastatic insulinoma with refractory hypoglycemia: French multicenter series

> “Twelve patients with metastatic insulinoma and refractory hypoglycemia who were treated with everolimus between May 2007 and June 2011 were reviewed.”
> “After a median duration of 6.5 months (range 1-35+ months), median time to the first recurrence of symptomatic hypoglycemia was 6.5 months (range 0 to 35+ months).”
> “Three patients discontinued everolimus because of cardiac and/or pulmonary adverse events at 1, 1.5, and 7 months after initiation, which led to two deaths.”

Source: [Bernard et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23392213/)

<a id="topic-2.2.2.1.6-4"></a>

###### Everolimus in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “Overall survival (OS) was longest with SSA at 84.67 months, followed by CAPTEM at 81.67 months and everolimus at 74.07 months.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.6-5"></a>

###### Everolimus label: hyperglycemia incidence

> “Hyperglycemia, hypercholesterolemia, and hypertriglyceridemia have been reported in patients taking AFINITOR/AFINITOR DISPERZ at an incidence up to 75%, 86%, and 73%, respectively.”

Source: [Afinitor prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/022334s055lbl.pdf)

<a id="topic-2.2.2.1.6-6"></a>

###### Manufacturer characterization of mTOR inhibitor use

> “mTOR-inhibitors are used off-label and have potentially serious side effects”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

Additional sources: [Kulke et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19129539/); [Pavel et al. (2020)](https://doi.org/10.1016/j.annonc.2020.03.304)

<a id="heading-2.2.2.1.7"></a>

###### 2.2.2.1.7 Peptide Receptor Radionuclide Therapy

<a id="topic-2.2.2.1.7-1"></a>

###### PRRT for hypoglycemia in metastatic insulinoma: ENETS 2023 guidance

> “PRRT was performed in 14 patients, 13 of whom (92.8%) had complete or partial control of hypoglycaemia syndrome”
> “In another single centre series, symptomatic response to PRRT in terms of hypoglycaemia was observed in six out of nine patients with malignant insulinoma.”
> “Consequently, both PRRT with 177Lu-DOTATATE and everolimus can be considered in advanced insulinoma cases with hypoglycaemia refractory to SSA, especially in those cases with concurrent progressive disease [4, C].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.7-2"></a>

###### PRRT: requirement for somatostatin receptor expression, symptomatic response, and serious adverse effects

> “It is imperative to demonstrate expression of SSTR on the tumors using pretreatment 68Ga DOTANOC / DOTATOC / DOTATATE PET/CT”
> “Favorable symptomatic and biochemical responses using PRRT with 177Lu-DOTATATE have been obtained in small patient series with functioning metastatic gastrointestinal tract and pancreas NEN like metastatic insulinomas, even when there was no visible tumor regression”
> “However, rare (2%) but serious side effects include severe and irreversible bone marrow disease (pancytopenia, acute myelogenous leukemia, and myelodysplastic syndrome)”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.7-3"></a>

###### PRRT in metastatic insulinoma: Basel single-center long-term series

> “In the long term, a total of 21 of 26 patients (81%) demonstrated improvement during the observation period”
> “The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3”
> “In 58% of patients (15/26), a reduction of antihypoglycemic medication was achieved after PRRT during the observation period”
> “The median OS was 19.7 mo (95% CI, 6.5–32.9 mo)”
> “Of the 26 patients, 5 (19%) experienced transient hypoglycemia after injection of [90Y]Y-DOTATOC/[177Lu]Lu-DOTATOC.”

Source: [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/)

<a id="topic-2.2.2.1.7-4"></a>

###### Lutetium Lu 177 dotatate in malignant insulinoma: two Australian centers

> “Of 15 patients (seven female; median age 60, range 26-82) treated for intractable hypoglycaemia, WHO grade (G) was known in 12 patients (three G1, six G2 and three G3).”
> “Resolution of hypoglycaemia was observed in 14/15 (93%) patients after a median of 2.5 months (range 0.2-23.5), but recurred in 7/14 cases after a median of 17.7 months (range 7.6-48.3).”
> “In all seven cases, PRRT re-treatment was successful.”
> “Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

<a id="topic-2.2.2.1.7-5"></a>

###### PRRT in malignant insulinoma: hypoglycemia control and overall survival, Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “PRRT demonstrated a median OS of 49.73 months.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.7-6"></a>

###### Lutetium Lu 177 dotatate in functioning pancreatic neuroendocrine tumors including 14 insulinomas

> “Thirty-four patients with a metastatic functioning pNET (European Neuroendocrine Tumor Society grade 1 or 2) were included: 14 insulinomas, 5 VIPomas, 7 gastrinomas, and 8 glucagonomas.”
> “Subacute hematological toxicity, grade 3 or 4 occurred in 4 patients (12%) and a hormonal crisis in 3 patients (9%).”
> “71% of patients with uncontrolled symptoms had a reduction of symptoms and a more than 80% decrease of circulating hormone levels was measured during follow-up.”

Source: [Zandee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30566620/)

<a id="topic-2.2.2.1.7-7"></a>

###### Lutetium Lu 177 dotatate: labeled indication

> “LUTATHERA is indicated for the treatment of adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.”

Source: [Lutathera prescribing information (2024)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf)

<a id="heading-2.2.2.1.8"></a>

###### 2.2.2.1.8 Systemic Antitumor Therapy

<a id="topic-2.2.2.1.8-1"></a>

###### Chemotherapy and targeted agents for functioning pancreatic neuroendocrine tumors: ENETS 2023 guidance

> “Systemic treatment with chemotherapy or peptide receptor radionuclide therapy (PRRT) plays a key role for selected patients for both control of tumour growth and hormonal symptoms.”
> “One of the most commonly used chemotherapy regimens is capecitabine associated with temozolomide which had a response rate of 40% in grade 1–2 Pan-NET in a prospective, multicentre, randomised phase II trial.”
> “Historically, streptozotocin is well-known for its diabetogenic effects, making it a suitable alternative for high grade or clinically aggressive insulinomas.”
> “PRRT, chemotherapy, everolimus or sunitinib should generally be reserved for SSA-refractory cases [4, B].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.8-2"></a>

###### Cytotoxic chemotherapy and sunitinib in malignant insulinoma: effect on hypoglycemia

> “Historically, (combinations of) 5-fluorouracil, doxorubicin, and streptozotocin have been used for the treatment for inoperable functioning and nonfunctioning pancreatic high-grade NET, including malignant insulinomas”
> “However, these drugs and their combinations cause considerable toxicities.”
> “Again, it can be expected that considerable debulking following chemotherapy will be associated with less frequent and less severe hypoglycemias.”
> “In contrast to everolimus, sunitinib does not directly influence insulin secretion or insulin resistance.”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Chemotherapeutic regimes including streptozocin, 5‐fluorouracil, capecitabine and temozolomide (CAPTEM) and cisplatin with etoposide have been used in the management of metastatic neuroendocrine tumour alongside everolimus and somatostatin analogues, though evidence for their independent effect on hypoglycaemia is lacking”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.8-3"></a>

###### Capecitabine-temozolomide, other chemotherapy, and streptozocin in malignant insulinoma: Mayo Clinic cohort

> “PRRT demonstrated the highest efficacy in controlling hypoglycemia (93%), followed by CAPTEM (68%) and everolimus (62%).”
> “SSA, chemotherapy, and streptozocin were less effective, with hypoglycemic improvement seen in 37.5, 33.3, and 28.6% of patients, respectively.”
> “In contrast, chemotherapy and streptozocin-based therapies had significantly shorter OS times of 15.23 and 8.35 months, respectively.”

Source: [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/)

<a id="topic-2.2.2.1.8-4"></a>

###### Cabozantinib: labeled indication in pancreatic neuroendocrine tumors

> “CABOMETYX is indicated for the treatment of adult and pediatric patients 12 years of age and older with previously treated, unresectable, locally advanced or metastatic, well-differentiated pancreatic neuroendocrine tumors (pNET).”

Source: [Cabometyx prescribing information (2025)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208692s019lbl.pdf)

<a id="topic-2.2.2.1.8-5"></a>

###### Manufacturer statements on tumor-directed therapy and hypoglycemia, insulinoma and NICTH

> “Tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or NICTs.”
> “In many cases, tumor-directed therapies are administered concurrently with medical therapies for hypoglycemia and in other cases successful treatment of hypoglycemia often enables the initiation and/or continuation of tumor-directed therapies, as indicated.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="heading-2.2.2.1.9"></a>

###### 2.2.2.1.9 Liver-directed Therapy

<a id="topic-2.2.2.1.9-1"></a>

###### Embolization and cytoreduction for uncontrolled functioning syndromes: ENETS 2023 guidance

> “If the disease is predominantly located in the liver, transarterial bland, chemo- or radioembolisation could be a treatment option in cases of uncontrolled functioning syndrome despite optimal medical therapy [2b, B].”
> “Because of the high morbidity risk associated with this technique in cases of high metastatic load in the liver, the indication must be confirmed in a NET-dedicated multidisciplinary team attended by an interventional radiologist.”
> “Radioembolisation together with chemoembolisation recently proved to be highly effective in controlling hypoglycaemia in a series of seven patients with malignant insulinoma, resulting in an initial clinical success rate of 100% and in an overall clinical success rate of 85%”
> “Cytoreductive surgery can be considered for patients with functioning tumours when ≥70%–90% of visible disease can be debulked.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.9-2"></a>

###### Liver-directed options for metastatic insulinoma

> “Also, liver metastases can be resected, or treated by trans-arterial bland or chemo-embolization, radioembolization, radiofrequency ablation, microwave and cryoablation, high-intensity focused ultrasound, laser, brachytherapy, and irreversible electroporation depending on the local availability”
> “However, most aggressive malignant metastatic insulinomas cannot be cured by surgery or ablation procedures alone and require supportive measures, medical antihormonal, and antitumor treatment”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.1.9-3"></a>

###### Bland hepatic artery embolization for refractory hypoglycemia from insulinoma liver metastases

> “Twenty patients (10 women, 10 men; mean age, 56 years; range, 18-84 years) were identified who individually underwent 1 (n = 7), 2 (n = 5), 3 (n = 5), 4 (n = 2), or 5 (n = 1) HAEs, for an overall total of 45 HAEs.”
> “Postprocedural hypoglycemic symptom relief after the first HAE was reported in 100% (n = 20) of patients before discharge or at follow-up.”
> “Post-HAE hypoglycemia recurrence occurred in 60% (n = 12) of patients with a median time to first hypoglycemia recurrence of 2 months (mean, 14 months; range, 0.2-60 months).”
> “After the first HAE, median HFS was 14.5 months, and median OS was 16 months.”
> “IV fluids containing dextrose given preprocedurally in 85% (n = 17) of patients were stopped either immediately postprocedure, on resumption of oral intake, or before discharge, in all patients after the first HAE.”
> “One patient experienced labile postprocedure blood glucose levels requiring intensive care unit admission for intravenous dextrose.”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.2.1.9-4"></a>

###### Chemoembolization and radioembolization for intractable hypoglycemia in metastatic insulinoma

> “Seven patients were identified (4 male patients).”
> “Technical success rate was 97% (32/33 procedures) with an initial clinical success rate of 100%, defined as absence of recurrent symptomatic hypoglycemia within 1 month after first cycle of LDT and overall clinical success rate of 85%.”
> “Random daytime glucose levels increased from 75.0 (SD, 26) mg/dL to 152.8 (SD, 52.4) mg/dL after LDT.”
> “The mean time to recurrence of intractable hypoglycemia was 21 (SD, 9) months.”

Source: [Habibollahi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32541627/)

<a id="topic-2.2.2.1.9-5"></a>

###### Deferral of tumor-directed therapy because of hypoglycemia: manufacturer statement

> “Tumor-directed therapies (e.g., embolization, radio therapy, chemotherapy) deferred because of hypoglycemia”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="heading-2.2.2.1.10"></a>

###### 2.2.2.1.10 Glucocorticoids and Recombinant Growth Hormone

<a id="topic-2.2.2.1.10-1"></a>

###### Glucocorticoids for refractory hypoglycemia in insulinoma: ENETS 2023 guidance

> “First-line medical therapy for advanced insulinoma consists of diazoxide (50–600 mg daily).”
> “In cases of refractory hypoglycaemia, incidental descriptions also support the use of glucocorticoids, verapamil, and diphenylhydantoin [5, D].”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

<a id="topic-2.2.2.1.10-2"></a>

###### Glucocorticoids in insulinoma: dose and adverse effects

> “Glucocorticoids are sometimes used to control the hypoglycemia but their chronic use poses a significant risk for side effects (eg, weight gain, neuropsychiatric disturbances, hypertension, secondary [opportunistic] infections).”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “Glucocorticoids inhibit insulin release and increase peripheral insulin resistance and have been used in the management of refractory hypoglycaemia at a low dose (prednisolone 2.5 mg daily, dexamethasone 0.5−4 mg) where other agents have been ineffective”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.1.10-3"></a>

###### Glucocorticoids and recombinant growth hormone in NICTH: clinical review

> “In such cases, we suggest consideration of local antitumor therapies for disease control and trial of glucocorticoids alone or in combination with GH.”
> “Diazoxide and octreotide have no role in NICTH.”
> “Glucocorticoids (including dexamethasone, hydrocortisone, prednisolone, and prednisone, typically in doses equivalent to prednisone 30–60 mg/d) are the most extensively described medical therapy for NICTH”
> “Recombinant human GH (rhGH) at supraphysiological doses of 3–12 mg daily has been successful in many cases”
> “Additionally, we propose that cost could be a limiting factor, especially for long-term therapy.”
> “Combination therapy was successful (including freedom from iv glucose or dextrose) in multiple cases where monotherapy with either failed”
> “Although there are no randomized controlled trials to guide therapy, ample case reports and series are available in the literature over the past quarter century.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.1.10-4"></a>

###### Glucocorticoid dose threshold and reversibility in NICTH: case series

> “Therapeutic treatment with glucocorticoids confirmed previous studies showing the suppressive effect on tumour (big) IGF-II production.”
> “The present data show that the effect was dose-dependent and reversible if doses were below a critical level.”
> “This effectiveness was only achieved when the dose exceeded a threshold level specific to the patient.”

Source: [Teale and Wark (2004)](https://pubmed.ncbi.nlm.nih.gov/15049960/)

<a id="topic-2.2.2.1.10-5"></a>

###### Glucocorticoids compared with growth hormone in NICTH: effect on big IGF-II

> “Two groups each of 4 patients, all diagnosed as cases of NICTH, were treated with either hGH or glucocorticoids.”
> “Glucocorticoid therapy has been demonstrated to consistently reverse the biochemical abnormalities caused by tumour-derived big IGF-II compared with the potentially adverse stimulatory effects of hGH treatment in causing increases in serum levels of big IGF-II.”

Source: [Teale and Marks (1998)](https://pubmed.ncbi.nlm.nih.gov/9876347/)

<a id="topic-2.2.2.1.10-6"></a>

###### Glucocorticoid minimum effective doses and growth hormone combination in IGF-2-mediated hypoglycemia

> “The minimum effective dose in one review of NICTH with solitary fibrous tumours was 25 mg/day for prednisolone, 32 mg/day for methylprednisolone, and 2 mg/day for dexamethasone”
> “Recurrent hypoglycemia is also seen when the glucocorticoid dose is reduced below the aforementioned thresholds, limiting their long-term utility”
> “The combination of rGH with glucocorticoids at low doses, as in case 2, is an effective regimen with minimal adverse effects in patients with inoperable tumours”
> “When the tumour is unresectable, moderate-dose glucocorticoids, low-dose glucocorticoids in combination with recombinant growth hormone, and pasireotide are medical therapies with promising results in controlling NICTH.”

Source: [Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10959053/)

<a id="topic-2.2.2.1.10-7"></a>

###### Frequency of glucocorticoid use in IGF-2-mediated hypoglycemia: systematic review of 233 patients

> “Medication therapy with corticosteroids, octreotide and diazoxide was used in 91 (39.1%), 18 (7.7%) and 16 (6.9%) cases, respectively.”
> “Management such as octreotide, corticosteroids, diazoxide, embolization, radiotherapy and surgical resection have disparate success rates.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="topic-2.2.2.1.10-8"></a>

###### Manufacturer statements on medical therapy in NICTH

> “Dextrose, oral glucocorticoids, and glucagon (diazoxide and somatostatin analogs are not effective treatments for hypo from IGF-2 tumors)”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

Additional sources: [Cryer et al. (2009)](https://pubmed.ncbi.nlm.nih.gov/19088155/)

<a id="heading-2.2.2.1.11"></a>

###### 2.2.2.1.11 Limitations of Current Therapies

<a id="topic-2.2.2.1.11-1"></a>

###### Summary: surgery and ablation for benign and localized insulinoma

- Surgical resection is the guideline treatment for localized insulinoma. The NANETS surgical guideline gives a 98% biochemical cure rate and a 6% chance of recurrence at 10 years after resection of a localized insulinoma.
- Operative morbidity is the main limitation. In 198 patients (106 enucleations and 92 pancreatic resections), the rate of clinically significant pancreatic fistula was 18%, enucleations had a higher reoperation rate than pancreatic resections (8.5% vs 1%), and new exocrine (1.5%) and endocrine (4%) insufficiency followed pancreatic resections only. In 80 patients operated for sporadic insulinoma over three decades, mortality was 6% (n = 5), morbidity 72%, and pancreatic fistula 44%, although surgery was curative in all patients. In 74 patients, an open approach (28 patients) was associated with more grade III/IV complications (32.1% vs 19.6%) and more 30-day readmissions (42.9% vs 17.4%) than a minimally invasive approach (46 patients).
- Recurrence after resection was 21% at 10 and 20 years in patients with MEN I, and 5% at 10 years and 7% at 20 years in patients without MEN I, in one cohort.
- EUS-guided radiofrequency ablation is an option in ENETS guidance for localized insulinomas of 2 cm or less in patients unfit for surgery, with confinement to expert centers until long-term survival and recurrence data are available. In a propensity-matched comparison of 89 patients per group, adverse events occurred in 18.0% after ablation and 61.8% after surgery, clinical efficacy was 95.5% and 100%, median follow-up was 23 and 37 months, and 15 lesions (16.9%) recurred after ablation. A randomized trial comparing ablation with surgery (NCT05735912) is registered.

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318); [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/); [Crippa et al. (2012)](https://pubmed.ncbi.nlm.nih.gov/22430908/); [de Carbonnières et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33975801/); [Patel et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42362418/); [Service et al. (1991)](https://pubmed.ncbi.nlm.nih.gov/1677058/); [Crinò et al. (2023)](https://pubmed.ncbi.nlm.nih.gov/36871765/); [ClinicalTrials.gov NCT05735912](https://clinicaltrials.gov/study/NCT05735912)

<a id="topic-2.2.2.1.11-2"></a>

###### Summary: medical therapy for hypoglycemia in insulinoma

- Dietary measures (fractioned meals with slowly absorbed carbohydrates, bedtime meals) are the basis of hypoglycemia control; nocturnal tube feeding or IV glucose through a central catheter may be needed in severe recurrent hypoglycemia. The glucagon (Gvoke) label lists insulinoma as a contraindication because glucagon may stimulate insulin release from the tumor, and states that the product is not approved for continuous infusion.
- Diazoxide is the first-line medical therapy for advanced insulinoma in ENETS guidance and controls hypoglycemia in 50 to 60% of cases according to the NANETS surgical guideline. Dose-limiting adverse effects (fluid retention and edema, palpitations, nausea, anorexia, hirsutism) occur in up to 80% of patients in one review. The label directs discontinuation if diazoxide is not effective after 2 or 3 weeks and warns of fluid retention that may precipitate congestive heart failure, ketoacidosis, nonketotic hyperosmolar coma, and thrombocytopenia. In 20 patients with insulinoma, diazoxide was effective in 9 and ineffective in 9, all 9 responders had benign insulinoma, and 5 patients had unacceptable thrombocytopenia. In 6 patients with inoperable insulinoma, 5 developed edema and 2 congestive heart failure. In a UK survey of 40 patients, side effects occurred in 47%, 59% were symptom free, and 38% had occasional symptoms.
- Somatostatin analogs can paradoxically aggravate hypoglycemia by suppressing glucagon, so a monitored trial of short-acting octreotide is advised before a long-acting formulation. Octreotide was effective in 10 of 17 patients in one series and 14 of 21 in another. The octreotide LAR and lanreotide labels warn of hypoglycemia or hyperglycemia, and their quoted indications are acromegaly, carcinoid and VIPoma symptoms, and progression-free survival in GEP-NETs. Pasireotide is used off-label; in 17 published cases, 6 (35%) showed no improvement, with no improvement in 55% of aggressive and 16% of indolent insulinomas.
- Glucocorticoids for refractory hypoglycemia rest on incidental descriptions in ENETS guidance (level of evidence 5, grade D), and chronic use carries weight gain, neuropsychiatric disturbances, hypertension, and opportunistic infections.

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/); [Gvoke prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/212097s012lbl.pdf); [Howe et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7029300/); [Proglycem prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/017453s025lbl.pdf); [Niitsu et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30504655/); [Komatsu et al. (2016)](https://pubmed.ncbi.nlm.nih.gov/26598136/); [Gill et al. (1997)](https://pmc.ncbi.nlm.nih.gov/articles/PMC2431498/); [Vezzosi et al. (2005)](https://pubmed.ncbi.nlm.nih.gov/15879362/); [Vezzosi et al. (2008)](https://pubmed.ncbi.nlm.nih.gov/18031316/); [Sandostatin LAR Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/021008s049lbl.pdf); [Somatuline Depot prescribing information (2024)](http://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022074s032lbl.pdf); [Vega-Beyhart et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40165498/)

<a id="topic-2.2.2.1.11-3"></a>

###### Summary: malignant and metastatic insulinoma

- In 121 patients with malignant insulinoma, resection was performed in 64%, and 5-year overall survival was 84% with surgery and 14% without. A clinical review states that most aggressive malignant metastatic insulinomas “cannot be cured by surgery or ablation procedures alone” and require medical and antitumor treatment.
- Hypoglycemia control in one malignant insulinoma cohort was 93% with PRRT, 68% with capecitabine-temozolomide, 62% with everolimus, 37.5% with somatostatin analogs, 33.3% with chemotherapy, and 28.6% with streptozocin.
- Everolimus: ENETS guidance describes limited tolerance. In 12 patients with metastatic insulinoma and refractory hypoglycemia, median time to first recurrence of symptomatic hypoglycemia was 6.5 months, and 3 patients discontinued for cardiac or pulmonary adverse events, which led to two deaths. The manufacturer of ersodetug states that mTOR inhibitors are used off-label.
- PRRT requires demonstrated somatostatin receptor expression and carries a 2% rate of serious bone marrow disease. In 15 patients treated with lutetium Lu 177 dotatate, hypoglycemia resolved in 14 and recurred in 7 of 14 after a median of 17.7 months; G3/4 myelosuppression occurred in 4 of 15 and hypoglycemia flare requiring hospitalization over 48 hours in 7 of 15. In 26 patients, 5 (19%) had transient hypoglycemia after injection, and hormonal crisis occurred in 3 of 34 patients (9%) with functioning pancreatic tumors in another series.
- Cytotoxic chemotherapy causes considerable toxicities, and evidence for an independent effect of chemotherapy regimens on hypoglycemia is lacking according to one review.
- Liver-directed therapy carries a high morbidity risk with high hepatic metastatic load in ENETS guidance. After bland hepatic artery embolization in 20 patients, hypoglycemia recurred in 60% at a median of 2 months; after chemoembolization and radioembolization in 7 patients, mean time to recurrence of intractable hypoglycemia was 21 months.
- The manufacturer states that tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or non-islet cell tumors, and that such therapies are deferred because of hypoglycemia.

Source: [Sada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7678752/); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/); [Koch et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40439997/); [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318); [Bernard et al. (2013)](https://pubmed.ncbi.nlm.nih.gov/23392213/); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/); [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/); [Zandee et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/30566620/); [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/); [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/); [Habibollahi et al. (2020)](https://pubmed.ncbi.nlm.nih.gov/32541627/); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.2.1.11-4"></a>

###### Summary: non-islet cell tumor hypoglycemia

- Complete surgical resection is curative for hypoglycemia, but in many cases total resection is delayed or not feasible. In a systematic review of published cases of IGF-2-mediated hypoglycemia, surgery was used in 110 cases (47.2%), and the overall recovery rate was 77% (172 of 223 cases with outcomes).
- When prompt resection is not feasible, IV glucose or dextrose often does not suffice. Continuous glucagon infusion and parenteral nutrition are limited by the need for continuous IV infusion, and long-term parenteral nutrition is “not a desirable long-term strategy” because of venous access complications, bloodstream infections, liver toxicity, electrolyte imbalances, and cost. In a series of 4 patients with NICTH and liver metastases, glucose did not rise after glucagon in 2.
- Diazoxide and octreotide have no role in NICTH in one clinical review, which found diazoxide unsuccessful in every case reviewed. In the systematic review, octreotide was used in 9 recovered patients (5.2%) and 9 who died (17.6%) (p = .01). The manufacturer states that diazoxide and somatostatin analogs are not effective for hypoglycemia from IGF-2 tumors.
- Glucocorticoids, used in 91 cases (39.1%) in the systematic review, are effective only above a patient-specific dose threshold. Minimum effective doses in one review of solitary fibrous tumors were 25 mg/day of prednisolone, 32 mg/day of methylprednisolone, and 2 mg/day of dexamethasone, and recurrence below these thresholds limits long-term use. Recombinant growth hormone at 3 to 12 mg daily has been successful in many cases, cost may limit long-term use, and growth hormone may increase serum big IGF-II. No randomized controlled trials guide therapy.

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/); [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/); [Hoff and Vassilopoulou-Sellin (1998)](https://pubmed.ncbi.nlm.nih.gov/9554538/); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Teale and Wark (2004)](https://pubmed.ncbi.nlm.nih.gov/15049960/); [Vu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10959053/); [Teale and Marks (1998)](https://pubmed.ncbi.nlm.nih.gov/9876347/)

<a id="heading-2.2.2.2"></a>

##### 2.2.2.2 Place in Treatment, Anticipated Use, and Care Setting

<a id="topic-2.2.2.2-1"></a>

###### Summary: place in therapy

- Ersodetug is investigational and has no approved indication. The FDA orphan drug designation names the treatment of hypoglycemia due to tumor-associated hyperinsulinism, the FDA breakthrough therapy designation names hypoglycemia caused by tumor HI, and the European Union orphan designation (12 January 2024) names insulinoma.
- The studied use is add-on therapy. The phase 3 upLIFT trial enrolls adults 18 years and older with an islet cell or non-islet cell tumor and biochemical evidence of tumor hyperinsulinism who have not achieved adequate control with usual standard-of-care therapies and require IV glucose infusion and/or parenteral nutrition for 7 days or more. Participants receive ersodetug 9 mg/kg weekly for 8 weeks “as an add-on to standard of care”, then may continue in long-term extension at a dosing frequency of every 2 to 4 weeks. Of the 16 enrolled participants, 12 have malignant islet cell tumors (insulinomas) and 4 have non-islet cell tumors.
- In the expanded access publication, all 8 individuals had received and were refractory to at least 3 standard-of-care therapies (diazoxide, somatostatin analogs, everolimus, and/or corticosteroids), and 6 of 8 were hospitalized at entry. Ersodetug was given intravenously over 30 minutes, and the manufacturer states that hospitalized patients were discharged and received maintenance doses as outpatients. Expanded access continues through a registered program (NCT07262970), with drug supplied at no cost under compassionate use programs.
- The manufacturer describes medical therapy as needed from diagnosis to surgery, when surgery is contraindicated or refused, and chronically in patients who cannot be cured by surgery, and names peri-operative management of solitary or benign tumors and solitary or benign tumors where surgery may not be ideal as potential additional settings. It expects to focus its launch on National Cancer Institutes and academic medical centers, where it believes 60% of patients are managed (about 1,000 prescribers and 300 centers), and expects payers to require prior authorization aligned to the label with a step through diazoxide for patients with insulinoma, with reimbursement through a J-code (buy and bill).
- A 2024 clinical review of insulinoma reports successful use of RZ358 in one patient with malignant insulinoma and severe refractory hypoglycemia.

Source: [FDA Orphan Drug Designations and Approvals (2024)](https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=966723); [Rezolute tumor HI breakthrough therapy release (2025)](https://ir.rezolutebio.com/news/detail/354/rezolute-receives-breakthrough-therapy-designation-from-fda-for-ersodetug-in-the-treatment-of-hypoglycemia-due-to-tumor-hyperinsulinism); [EMA insulinoma orphan designation (2024)](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2879); [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism); [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992); [Rezolute Form 10-K (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110420/rzlt-20260630x10k.htm); [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/); [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm); [ClinicalTrials.gov NCT07262970](https://clinicaltrials.gov/study/NCT07262970); [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm); [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.2-2"></a>

###### Studied use: add-on to standard of care in adults requiring continuous intravenous glucose

> “Eligible participants requiring continuous intravenous (IV) glucose receive ersodetug 9 mg/kg per week for 8 weeks, as an add-on to standard of care.”
> “Following this 8-week pivotal treatment period, all participants may receive ersodetug at a reduced dosing frequency in long-term extension.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

> “The objectives of this study are to evaluate the glycemic efficacy, safety, and tolerability of ersodetug as add-on to standard of care (SOC) therapy for treatment of hypoglycemia in patients with Tumor Hyperinsulinism (Tumor HI).”
> “Clinical diagnosis of neuroendocrine tumor (NET) (ICT or NICT) with biochemical evidence of tumor hyperinsulinism (hypoglycemia with inappropriately elevated insulin or insulin-like growth factor (IGF)/variant suppression) confirmed via laboratory assessment who have failed to achieve adequate control of hypoglycemia with usual SOC anti-hypoglycemic therapies, per investigator judgement.”
> “Currently requiring IV glucose infusion and/or parenteral nutrition for ≥7 days for the management of refractory hypoglycemia (prior to administration of the 1st dose of ersodetug).”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

<a id="topic-2.2.2.2-3"></a>

###### Points in the disease course at which medical therapy for hypoglycemia is needed: manufacturer statements

> “During the period from diagnosis to surgical treatment, or if surgery is contraindicated or refused, medical treatments are often necessary to directly manage the HI and hypoglycemia induced by the tumor.”
> “Additionally, chronic medical management of refractory hypoglycemia is often necessary for patients who cannot be cured by surgery, such as those with extensive disease of the pancreas, multi-focal insulinomas, inoperable or unresectable benign or malignant insulinomas, metastatic insulinomas, non-pancreatic insulinomas or NICT hypoglycemia resulting from a variety of other tumors.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.2.2-4"></a>

###### Prior therapies and hospitalization of the expanded access population

> “All individuals had received and were refractory to at least 3 standard-of-care therapies, including diazoxide, short- and long-acting somatostatin analogs, everolimus, and/or corticosteroids.”
> “Six of the 8 individuals were hospitalized at EAP entry (median, 28 days; range, 4-66 days), largely due to glycemic instability and the need for inpatient or intensive parenteral glucose support.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “All patients received ersodetug in open-label fashion at doses of 6 or 9 mg/kg every 1-2 weeks initially, followed by a frequency of every 2-4 weeks as tolerated, as add on to standard of care (e.g. diazoxide, somatostatin analogues, etc.), which could be weaned as appropriate”

Source: [Patti et al. (2026)](https://rezolutebio.com/wp-content/uploads/2026/06/PSTR006_RZLT_ENDO-poster_Tumor-H_3x4_ssREL.pdf)

<a id="topic-2.2.2.2-5"></a>

###### Care setting: inpatient initiation and outpatient maintenance infusions

> “Ersodetug was administered intravenously over 30 minutes at an initial dose of 6 or 9 mg/kg, given either weekly or every other week initially, followed by a frequency of every 2-5 weeks, as appropriate, at the discretion of the treating physician.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

> “hospitalized patients were able to be discharged and receive maintenance ersodetug doses on an outpatient basis, with durable benefit.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

<a id="topic-2.2.2.2-6"></a>

###### Launch focus and concentration of treating centers

> “We believe 60% of these patients are managed at the National Cancer Institutes and academic medical centers, which will be our primary focus at launch.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “~1,000 HCPs treat 60% of patients”
> “300 centers manage 60% of patients”
> “High penetration with a small number of treaters at National Cancer Institutes and Academic Medical Centers”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-7"></a>

###### Anticipated payer management and reimbursement pathway

> “Expect to manage ersodetug with a prior authorization aligned to the label and a step-through diazoxide for patients with insulinoma”
> “Inclusion in NCCN and ENDO Society guidelines expedites the payer approval process”
> “Expect institutions, particularly NCI-designated centers, to be adept at navigating the medical exception process for payer approvals”
> “Reimbursement via J-code (buy and bill) simplifies the approval administration burden”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-8"></a>

###### Potential additional settings named by the manufacturer

> “Peri-operative management of solitary / benign tumors”
> “Solitary/benign tumors where surgery may not be ideal (e.g., contraindications or inability to localize)”
> “Inclusion in the NCCN guidelines helps patient identification and payer reimbursement”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.2-9"></a>

###### Mention of ersodetug in a clinical practice review of insulinoma

> “Recently, the successful use of RZ358 was reported in a patient with severe refractory hypoglycemia and a malignant insulinoma”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.2-10"></a>

###### Guideline framework for advanced functioning pancreatic neuroendocrine tumors

> “Management of each functioning Pan-NET syndrome in patients with advanced disease requires a tailored multimodal approach of supportive, surgical, interventional, hormonal and antiproliferative therapies [5, A].”
> “When dedicated supportive therapy for a functioning Pan-NET syndrome is insufficient, palliative SSA treatment can be initiated.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

Additional sources: [NCCN Neuroendocrine and Adrenal Tumors guideline](https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448)

<a id="heading-2.2.2.3"></a>

##### 2.2.2.3 Heterogeneity of Treatment Effect

<a id="topic-2.2.2.3-1"></a>

###### Ersodetug: tumor types enrolled and participants not yet responding in upLIFT, preliminary

> “The 16 enrolled participants include four with non-islet cell tumors and 12 with insulin-secreting malignant islet cell tumors (insulinomas).”
> “Three participants are still in the pivotal period of the study, including two who have not yet met the responder criterion.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.3-2"></a>

###### Ersodetug: response by tumor type (insulinoma or NICTH) in upLIFT

No evidence found.

<a id="topic-2.2.2.3-3"></a>

###### Ersodetug: non-responder with advanced cancer and poor performance status, upLIFT interim

> “This patient had Stage 4 metastatic colon cancer and a poor Eastern Cooperative Oncology Group performance status (ECOG 4).”
> “The reduction and eventual discontinuation of intravenous glucose were undertaken in the setting of hospice transition, so the participant is being counted as a non-responder for purposes of assessing the primary endpoint.”

Source: [Rezolute upLIFT interim release (2026)](https://ir.rezolutebio.com/news/detail/378/rezolute-announces-positive-interim-data-for-its-phase-3-uplift-study-of-ersodetug-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.3-4"></a>

###### Ersodetug: dose escalation and partial response in the expanded access series

> “One participant required escalation from 9 to 12 mg/kg every other week.”
> “One individual on home TPN initiated ersodetug contemporaneously with ablation of primary hepatic metastases, ultimately achieving a 50% reduction in intravenous carbohydrate support after dose escalation of ersodetug to 9 mg/kg biweekly.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.3-5"></a>

###### Comparator therapies: effectiveness differs between insulin-mediated and IGF-2-mediated hypoglycemia

> “DZ and SSAs do not work in NICTs because HI is not mediated by insulin”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

> “Diazoxide and octreotide have no role in NICTH.”

Source: [Bodnar et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC5393479/)

<a id="topic-2.2.2.3-6"></a>

###### Comparator therapies: somatostatin receptor expression in indolent and aggressive insulinoma

> “Expression of the SSTR2 and SSTR5 is generally low in indolent insulinoma cells, but usually high in aggressive insulinomas”
> “This test is required to avoid and timely intervene for a paradoxical aggravation of hypoglycemia via the suppression of counterregulatory glucagon secretion in patients with insulinomas which lack SSTR2 expression”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

<a id="topic-2.2.2.3-7"></a>

###### PRRT: tumor grade and recurrence of hypoglycemia

> “Patients with recurrent hypoglycaemia had a longer time to hypoglycaemia resolution (median 3.0 vs 0.5 months), were more likely G3 (57 vs 0%) and experienced higher mortality (86 vs 29%).”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

> “The average time of benefit (improvement of hypoglycemia) was 17.2 mo (range, 0–70.2 mo), with no differences between tumor grade 1, 2, or 3”

Source: [Friebe et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671384/)

<a id="topic-2.2.2.3-8"></a>

###### Hepatic artery embolization: timing of hypoglycemia recurrence and survival

> “Recurrence of hypoglycemia within 6 weeks of the first HAE was associated with a median OS of 8.5 months, and recurrence greater than 6 weeks post-HAE was associated with a median OS of 32.6 months (P = .03)”

Source: [Linch et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8643969/)

<a id="topic-2.2.2.3-9"></a>

###### NICTH: tumor origin and chronic liver disease as outcome modifiers

> “Chronic liver disease (CLD) was more likely to be associated with death than recovery (OR: 7.23, P: 0.03).”
> “Fibrous tumours were significantly associated with recovery compared to non‐fibrous ones, and the association was statistically significant (65.1% vs. 33%, p < .001).”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

<a id="heading-2.2.2.4"></a>

##### 2.2.2.4 Care Management Intervention Strategies

<a id="topic-2.2.2.4-1"></a>

###### Continuous glucose monitoring in insulinoma

> “A continuous glucose monitoring system can support patients in recognizing hypoglycemic events and prevent serious complications, especially during the night”

Source: [Hofland et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10940262/)

> “A CGMS could be a very useful tool in patients with insulinoma to early recognise a hypoglycaemic event and prevent severe complications.”
> “Furthermore, it is also possible to connect an infusion pump automatically administering glucose as required.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

> “Patients with insulinoma frequently have impaired hypoglycaemia awareness and evaluating treatment effect by symptoms alone may miss asymptomatic hypoglycaemia”
> “We advocate the use of continuous glucose monitoring in patients with insulinoma to reduce the incidence of severe hypoglycaemic episodes and enable dietary and medical intervention to be tailored for the individual and their lifestyle.”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.4-2"></a>

###### Dietitian-led nutritional management and patient and family education in insulinoma

> “Early education on hypoglycaemia identification and treatment for the patient and their family is critical.”
> “Patients with insulinoma should have specialist dietitian assessment and follow up comprising regular assessment of glycaemic control, nutritional education and intervention.”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="topic-2.2.2.4-3"></a>

###### Multidisciplinary team and tumor board management

> “The management of patients with a functioning Pan-NET syndrome is complex due to its heterogeneous presentation and multisystem involvement.”
> “Consequently, work-up and treatment of a (suspected) functioning syndrome should preferably be performed in a multidisciplinary setting and discussed in expert tumour boards.”

Source: [Hofland et al. (2023)](https://onlinelibrary.wiley.com/doi/10.1111/jne.13318)

> “Early referral to a dedicated neuroendocrine multidisciplinary team is critical considering the array of medical, oncological, interventional radiological and nuclear medical options.”

Source: [Brown et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29205458/)

> “Overall, our findings support an individualized, multidisciplinary treatment strategy integrating endocrine, oncological, and interventional expertise.”

Source: [Guerrero-Pérez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43000590/)

<a id="topic-2.2.2.4-4"></a>

###### Multidisciplinary eligibility review and coordination of tumor-directed therapy during ersodetug treatment

> “The eligibility criteria of all participants must be evaluated by a multidisciplinary team led by the PI, which must include an oncologist”

Source: [ClinicalTrials.gov NCT06881992](https://clinicaltrials.gov/study/NCT06881992)

> “Individuals resumed tumor-directed therapies or procedures as deemed appropriate by the multidisciplinary clinical care team, and these interventions were systematically recorded as part of the observational dataset.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.4-5"></a>

###### Monitoring for hypoglycemia flare during PRRT

> “Side-effects included G3/4 myelosuppression in 4/15 patients and hypoglycaemia flare (hospitalisation >48 h) in 7/15 patients.”
> “PRRT provides durable hypoglycaemic and oncologic disease control of MI with manageable toxicity including hypoglycaemia flare requiring multidisciplinary care.”

Source: [Pattison et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40424062/)

<a id="topic-2.2.2.4-6"></a>

###### Palliative care coordination at the end of life in metastatic insulinoma

> “Hypoglycaemia is a common cause of death for patients with metastatic insulinoma, whose disease has progressed despite multiple lines of therapy.”
> “Declining oral intake, anxiety around symptoms of hypoglycaemia, complex emotions regarding the cessation of CGM and difficulty in managing other symptoms such as pain should be navigated together with palliative care clinicians”

Source: [Howarth et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11788970/)

<a id="heading-2.2.2.5"></a>

##### 2.2.2.5 Other Product Development or Post-marketing Obligations Required by the FDA

Not applicable.

<a id="heading-2.2.2.6"></a>

##### 2.2.2.6 Ongoing Post-approval Monitoring

Not applicable.

<a id="heading-2.2.2.7"></a>

##### 2.2.2.7 Expected Outcomes of Therapy

<a id="topic-2.2.2.7-1"></a>

###### Ersodetug: primary endpoint and success threshold in upLIFT, preliminary

> “The primary efficacy endpoint in the upLIFT study is the proportion of patients able to achieve at least a 50% reduction from baseline in glucose infusion rate (GIR), a measure of intravenous glucose dependency for underlying hypoglycemia.”
> “To achieve statistical significance for the endpoint, the lower bound of the 95% confidence interval for percent of patients responding must exceed 30%, which equates to at least 9 responders (≥56%), based on enrollment of 16 participants.”
> “To date, 13 participants have met the responder criterion, including 12 who also achieved a complete discontinuation of IV glucose.”
> “Results for the completed study, including statistical analysis of the primary endpoint, are expected by mid-December 2026.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.7-2"></a>

###### Ersodetug: additional outcomes measured in upLIFT

> “Additional endpoints include the number of participants achieving complete discontinuation of GIR and time to discontinuation, time to discharge from the hospital as applicable, extent of hypoglycemia events and hypoglycemia time in the outpatient setting by self-monitored blood glucose and continuous glucose monitor, respectively, and patient reported quality of life.”

Source: [Rezolute upLIFT results release (2026)](https://ir.rezolutebio.com/news/detail/389/rezolute-announces-positive-results-from-the-phase-3-uplift-study-in-tumor-hyperinsulinism)

<a id="topic-2.2.2.7-3"></a>

###### Ersodetug: outcomes in the peer-reviewed expanded access series

> “Ersodetug therapy resulted in reduced hypoglycemia burden, ability to discontinue parenteral glucose infusion, allowing discharge from hospital, use of fewer antihypoglycemic therapies, and improved ECOG performance status in individuals with severe, refractory tumor HI.”
> “The median treatment duration with ersodetug (11.5 months, range 5-17) tended to correspond to patient lifespan in the setting of metastatic disease.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.2.7-4"></a>

###### Ersodetug: manufacturer-described outcomes of expanded access use

> “In summary, 75% of the patients receiving IV dextrose/total parenteral nutrition”
> “in the EAP achieved a complete discontinuation of IV dextrose/TPN.”

Source: [Rezolute Form 10-Q (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123364/rzlt-20260930x10q.htm)

> “Discharge from inpatient to outpatient care”
> “Ability to resume regular daily activities (e.g., driving)”
> “Resumption of tumor-directed therapies”
> “Potential increase in survival, as hypoglycemia-stabilized patients get anti-tumor treatment”

Source: [Rezolute October corporate presentation (2026)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)

<a id="topic-2.2.2.7-5"></a>

###### Current multimodal therapy in metastatic insulinoma: hypoglycemia control and survival

> “The final cohort comprised 275 patients with individual-level data.”
> “The liver was the predominant metastatic site (89.5%), while 82.8% of patients (111/134 evaluable) required nutritional support, reflecting the profound endocrine and metabolic burden of the disease.”
> “A disease control rate of 69.9% (153 evaluable) was observed with multimodal therapy, and definitive hypoglycemia control was achieved in 62.1% (164/264) of patients at last follow-up.”
> “Median overall survival from the time of metastatic diagnosis was 84 months (95% CI: 61.8-111), with a subset of patients surviving beyond 25 years.”

Source: [Guerrero-Pérez et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/43000590/)

> “Clinical data on 14 patients with metastatic insulinoma (metastases to the liver, skeleton, and lung) were reviewed in this descriptive study.”
> “The time of the 7 deaths ranged from 2.5 to 10.4 years (median time to death was 8.2 years).”
> “This compares to previous reports of median survival of about 2 years.”
> “Hypoglycemia was well-controlled and did not cause the deaths.”

Source: [Masharani et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11954510/)

<a id="topic-2.2.2.7-6"></a>

###### Current therapy in NICTH: recovery and mortality

> “Outcomes were available for 223 cases, and the overall recovery rate among all the participants was 77% (n = 172).”
> “Surgical removal was the most common treatment modality employed in 110 (47.2%) cases.”
> “In light of a high mortality rate, approximating 23%, identifying and comprehensively evaluating prognostic factors is paramount and necessitate further investigative efforts.”

Source: [Ata et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10897872/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
